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ABSTRACT 
 
 
My doctoral studies focused on the fatty acid metabolism of the deadly 
protozoan parasite, Trypanosoma brucei. Fatty acid metabolism in T. brucei can 
be broadly divided into two pathways, synthesis and uptake. In Chapters 2-4 I 
describe experiments investigating the parasite’s fatty acid synthesis pathway. 
Chapter 2 contains the initial characterization of acetyl-CoA carboxylase (ACC) in 
T. brucei. Knockdown of TbACC by RNA interference (RNAi) reduced parasite 
virulence in a mouse model, suggesting that TbACC has the potential to be 
utilized as a drug target. Chapters 3 and 4 explore the effects of two known ACC 
inhibitors, the aryloxyphenoxypropionate herbicide, haloxyfop and the green tea 
catechin, (−)-epigallocatechin-3-gallate (EGCG) on TbACC activity and parasite 
growth. Both compounds inhibited TbACC enzymatic activity and parasite growth 
in vitro. In Chapters 5 and 6 contain research that utilizes forward and reverse-
genetic techniques to study T. brucei fatty acid uptake. In Chapter 5 I begin to 
characterize the role of the parasite’s acyl-CoA synthetase genes in fatty acid 
uptake and growth. Further, I demonstrate that fatty acid uptake is in part a 
protein mediated process. Chapter 6 describes an RNAi screen for genes 
involved in T. brucei fatty acid uptake. Together these studies build upon our 
knowledge of the unique fatty acid metabolism of T. brucei, bringing us one step 
closer to a potential cure for this horrible disease.  
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CHAPTER ONE 
LITERATURE REVIEW 
AFRICAN TRYPANOSOMIASIS 
 Trypanosoma brucei is an early-branching protozoan parasite transmitted 
by the tsetse fly to its mammalian hosts. The parasite threatens over 6.2 million 
square miles in sub-Saharan Africa (FAO, Food and Agricultural Organization of 
the United Nations, 2007) where it causes fatal disease in humans. Between 
1998 and 2004 annual cases of African sleeping sickness were estimated to 
number 50,000 to 70,000 (WHO, 2010). More recently, in 2009, less than 10,000 
cases were reported. In some regions the infection rate of human African 
trypanosomiasis (HAT) is especially high, causing greater morbidity and mortality 
than either HIV/AIDS or malaria (WHO, 2010).  
Two subspecies of the parasite cause disease in humans. T. b. 
gambiense is most common on the western side of the Nile rift valley and causes 
a chronic infection that leads to death over a ~3 year period. T. b. rhodesiense is 
found primarily on the eastern side of the Nile rift valley and causes an acute 
infection that can result in death in as little as 3 weeks (Brun et al., 2010). T. b. 
brucei is the subspecies we utilize for laboratory experiments. Humans are 
resistant to infection by T. b. brucei because they possess a specialized type of 
high density lipoprotein called trypanolytic factor (TLF) causes parasite lysis 
when it is taken up via endocytosis (Wheeler, 2010). Cattle and other livestock 
lack TLF and are therefore sensitive to infection by T. b. brucei and a related 
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parasite, Trypanosoma congolense. These parasites are the causative agents of 
a devastating livestock disease called nagana (Baumgaertner et al., 2008). The 
disease makes agriculture in this lush, fertile landscape nearly impossible and 
results in $4.5 billion dollars of trypanosome-related agricultural losses each 
year. Much of the economic turmoil in this poverty-stricken region of sub-Saharan 
Africa stems from the inability to establish an efficient agricultural system in this 
uncultivatable “green desert” (FAO, Food and Agricultural Organization of the 
United Nations, 2007).  
HAT manifests two distinct clinical stages. In early-stage infections 
parasites are restricted to the bloodstream and lymph. Typical early-stage 
symptoms include fever, headache, and swollen lymph nodes. Late-stage 
symptoms occur after the parasite has invaded the central nervous system. 
Severe insomnia is often induced by disruptions of circadian rhythms. This 
disruption causes the lethargic coma-like state that is characteristic of the 
infection and the origin of the term “sleeping sickness”. Late-stage HAT may also 
bring about psychological conditions ranging from apathy to irritability (Brun et 
al., 2010).         
African Trypanosomiasis Treatment 
 There is no vaccine for African trypanosomiasis because the antigenic 
variability of the parasite confounds vaccine development (Brun et al., 2010; 
Horn et al., 2010).  Thus, current control options center on prevention and 
chemotherapy.  Prevention methods such as trapping, insecticide treatment, and 
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behavioral changes (e.g. grazing at night) are costly and/or potentially toxic to 
humans and cattle, while ultimately yielding incomplete protection (Enserink, 
2007).  
Successful treatment of HAT is dependent upon proper diagnosis of the 
parasite subspecies and disease phase. Hemolymphatic infections are 
diagnosed using either card agglutination tests or microscopic examination of 
blood and lymph node aspirates. However, detection of late-stage HAT requires 
a lumbar puncture to acquire cerebrospinal fluid (CSF) for analysis. Despite the 
invasive nature of a lumbar puncture, CSF screening is considered a necessary 
step in the diagnostic process, as two of the approved drugs are not suitable for 
last-stage treatment because they do not efficiently cross the blood-brain barrier 
(Fairlamb, 2003; WHO, 2010; Brun et al., 2010).    
The five compounds currently available for treating sleeping sickness each 
have substantial limitations (Fairlamb, 2003; Brun et al., 2010). Patients with an 
early-stage infection are treated with either Suramin or Pentamidine. Suramin is 
the front-line drug for early-stage T. b. rhodesiense infections. Besides having 
immediate life-threating side-effects, the trypanocidal activity of Suramin is slow 
and the mode of action remains a mystery. It is widely considered to have 
multiple cellular targets, a notion supported by the fact that drug resistance in 
field isolates has not been reported. Early-stage T. b. gambiense infections are 
typically treated with Pentamidine. The drug has relatively high trypanocidal 
activity, and resistance in field isolates has not been reported. The compound is 
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taken up by at least three cell membrane transporters and causes a disruption in 
kinetoplast DNA replication by inhibiting mitochondrial topoisomerase II. 
Pentamidine is also believed to reduce polyamine biosynthesis by inhibiting 
production of S-adenosylmethionine. However, Pentamidine has limited use 
because it does not cross the blood-brain barrier and has limited efficacy against 
T. b. rhodesiense.  
Late-stage T. b. gambiense infections can be treated with Eflornithine. The 
compound perturbs polyamine biosynthesis by irreversibly inhibiting ornithine 
decarboxylase. Treatment with Eflornithine is reasonably effective, but the 
medically-intensive administration (four daily infusions over 1-2 weeks) and high 
cost often force care-givers to utilize Melarsoprol, a much less desirable 
alternative. Because Melarsoprol is relatively inexpensive compared to 
Eflornithine, it is the most common chemotherapeutic agent for treatment of late- 
stage T. b. gambiense and T. b. rhodesiense infections. It is a highly-toxic, 
organic derivative of arsenic. Melarsoprol kills 5% of patients receiving treatment 
(McNeil, 2000). Drug administration is extremely painful because the water-
insoluble compound is dissolved in propylene glycol. Due to its widespread use, 
reports of Melarsoprol resistance are common. Treatment failures as high as 
30% have been reported in some regions (Fairlamb, 2003; WHO, 2010; Brun et 
al., 2010). 
 Nifurtimox, a drug approved for treatment of Trypanosoma cruzi infection, 
has also been utilized in combination with either Eflornithine or Melarsoprol to 
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treat late-stage cases of sleeping sickness. The results of the clinical trials have 
been somewhat conflicting, but a recent review of 9 different Nifurtimox-
combination therapy trials concluded that a Nifurtimox-Eflornithine combination 
was better tolerated than a Nifurtimox-Melarsoprol combination or Melarsoprol 
alone. Additionally, rates of relapse, a typical complication in treating late-stage 
HAT, were low when Nifurtimox-Eflornithine combination therapy was utilized. 
Thus, Nifurtimox combination therapies represent a new weapon in the battle 
against sleeping sickness (Fairlamb, 2003; Lutje et al., 2010). 
New drugs for the treatment of sleeping sickness are desperately needed. 
Of the 5 currently used compounds, Eflornithine was developed most recently, 
first synthesized in 1977. Suramin has been in use for over 90 years (Fairlamb, 
2003). These facts highlight the desperate need for new drugs and drug targets, 
making research into trypanosome biology of critical importance. My research 
represents progress towards developing new treatments for sleeping sickness. 
Trypanosoma brucei LIFE CYCLE 
 Within an infected mammalian host, the parasite lives and divides 
extracellularly in the blood stream and in late-stage infections, the cerebrospinal 
fluid. Rapid division occurs via binary fission, resulting in parasite titers 
exceeding 1x109 parasites/mL. This spike in parasitemia is followed by a 
developmental shift to the nonproliferative short stumpy form. As the infection 
progresses, parasites begin to cross the blood-brain barrier and accumulate in 
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the brain, eventually leading to coma and death (Matthews, 2005; Lee et al., 
2007). 
 The insect life stage begins when the tsetse fly takes a blood meal 
containing short stumpy forms from an infected mammal. The parasites replicate 
for a period in the insect’s midgut before traversing the midgut epithelium into the 
hemolymph. They then navigate through the hemolymph to invade the salivary 
glands where they undergo another developmental shift into metacyclic forms. 
These metacyclic form parasites can then be transmitted to another mammalian 
host when the fly takes its next blood meal (Matthews, 2005; Lee et al., 2007) 
(Fig. 1.1).  
Parasite Surface Coats 
 The surface coat proteins of the parasite are important for survival 
throughout its life cycle. In the mammalian bloodstream form (BF), the surface 
coat is composed of 107 identical copies of variant surface glycoprotein (VSG) 
(Ferguson et al., 1984). Each VSG molecule is attached to the cell membrane by 
a glycosylphosphatidylinositol (GPI) anchor whose fatty acid moiety is exclusively 
the 14-carbon fatty acid, myristate (Ferguson et al., 1984). This dense VSG coat 
allows the parasite to vary its surface antigens throughout the duration of an 
infection. Over 1000 genes code for the proteinaceous portion of VSG, giving the 
parasite a huge antigenic repertoire (Ferguson et al., 1999). This process of 
antigenic variation allows the trypanosome to be a very successful parasite; the 
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mammalian adaptive immune system is unable to mount an efficient attack 
against the ever-changing parasite surface coat.  
 The insect midgut, procyclic form (PF) parasites also depend heavily on 
their surface coat protein, procyclin (Richardson et al., 1988; Roditi et al., 1989). 
Procyclin may play a major role in protecting the trypanosome against proteolytic 
degradation while in the midgut of the tsetse fly (Acosta-Serrano et al., 2001). 
Each of the 106 procyclins per cell is attached to the cell membrane by a lyso-
GPI anchor, each requiring two fatty acid molecules, either 16 or 18-carbons in 
length (Butikofer et al., 1997). The parasite’s dependence upon GPI-anchored 
surface coat proteins during two life cycle stages highlights the high demand for 
copious quantities of fatty acids throughout its life cycle (Morita et al., 2000; Paul 
et al., 2001).       
Host Microenvironments 
 As the parasite moves through its life cycle, it encounters a number of 
diverse microenvironments: the mammalian blood and brain/CSF; and the insect 
midgut, hemolymph and salivary glands. Each of these environments is unique in 
their nutrient content. One example of a dramatic shift in environmental fatty acid 
availability occurs when the parasite moves across the blood-brain barrier; the 
CSF contains 99.8% less lipids than the blood (Roheim et al., 1979). Fatty acids 
are extremely important to the parasite. Besides constituting critical GPI anchor 
components for essential cell surface proteins, fatty acids play both functional 
roles (cell signaling molecules) and structural roles (principal elements of cellular 
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membranes) within the cell. Because of the extremely variable conditions and 
high demand for fatty acids, the parasite encounters host microenvironments 
where the available fatty acids are insufficient. To compensate, T. brucei can 
synthesize its own fatty acids. Thus, the parasites must have the ability to 
efficiently regulate its mechanism for de novo synthesis of fatty acids to meet its 
changing nutrient demands.  
FATTY ACID SYNTHESIS 
 Fatty acid synthesis (FAS) occurs in cycles of four enzymatic reactions 
that result in the extension of a growing acyl chain by two carbons with each 
successive cycle. The first reaction in the cycle involves the condensation of an 
acyl chain with a malonyl group, the two-carbon donor molecule; this reaction is 
catalyzed by a ketoacyl synthase. The ketoacyl intermediate then undergoes a 
reduction by ketoacyl reductase, dehydration by a dehydratase and final 
reduction by enoyl reductase, yielding a fatty acyl chain two carbons greater in 
length (Lee et al., 2007) (Fig. 1.2).  While all FAS includes the same four basic 
reactions, different types of FAS pathways have a number of important 
distinctions.  
 FAS pathways are separated into two groups: the eukaryotic type I and 
the prokaryotic-origin type II. The type I FAS pathway includes one or two very 
large multifunctional proteins, while the type II pathway utilizes four separate 
proteins, each with a discrete enzymatic function. Many eukaryotic organisms 
possess both pathways. However, the type II pathway is typically restricted to 
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organelles of prokaryotic origin (e.g., mitochondria, apicoplasts and chloroplasts) 
(Goodman et al., 2007; Lee et al., 2007; Stephens et al., 2007). Some 
eukaryotes also utilize microsomal elongases (ELO) as a component of their FAS 
machinery. ELO pathways utilize the same cycle of enzymatic reactions as type I 
or type II FAS, but typically extend only long chain fatty acids (16 to 18 carbons) 
to very long chain fatty acids, greater than 20 carbons in length (Toke et al., 
1996; Oh et al., 1997; Moon et al., 2001). ELO pathways are also distinct 
because they are associated with organellar membranes and utilize Coenzyme-A 
(CoA) rather than acyl carrier protein as a carrier molecule for acyl intermediates. 
T. brucei Fatty Acid Synthesis 
 Unlike most eukaryotes T. brucei lacks the typical components of the 
cytosolic type I FAS. In lieu of the conventional FAS pathway, the parasite 
depends completely upon an ELO pathway for the bulk synthesis of its fatty acids 
(Lee et al., 2006). This ELO pathway is set apart from others by the ability to 
synthesize fatty acids de novo from a 4-carbon primer, butyryl-CoA. The T. 
brucei ELO pathway consists of four different ketoacyl-CoA synthases with 
distinct, yet overlapping specificities for acyl-CoA chain lengths: ELO1 (C4:0 – 
C10:0), ELO 2 (C10:0 – C14:0), ELO 3 (C14:0 – C18:0). There is a fourth 
enzyme in the pathway, ELO4, but its use is restricted to elongation of long chain 
unsaturated fatty acids. The two reductases in the pathway have also been 
identified; the genome codes for two ketoacyl-CoA reductases and a single 
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enoyl-CoA reductase. The pathway’s dehydratase has yet to be identified (Lee et 
al., 2006; Lee et al., 2007). 
The distinct yet overlapping activities of the ELO proteins allows for a very 
efficient FAS mechanism in T. brucei. The modulation of each ELO’s enzymatic 
activity allows for the preferential production of specific chain length fatty acids, 
providing T. brucei the ability to adjust to its ever-changing environmental 
conditions and demands for fatty acids (Lee et al., 2007). In addition, the need for 
a dedicated FAS and elongation pathways is essentially eliminated, because the 
ELO pathway serves both purposes.  
 T. brucei also possess a second FAS pathway, a mitochondrial type II 
pathway. It consists of one acyl carrier protein (ACP), one ketoacyl-ACP 
synthase, three ketoacyl-ACP reductases, one or more currently unidentified 
dehydratases, and two enoyl-ACP reductases. Mitochondrial FAS is only 
responsible for 10% of total the FAS in the parasite and its primary products are 
C16:0 and C8:0. The C8:0 product is synthesized as a precursor for lipoic acid, 
which is an important prosthetic group for multiple mitochondrial enzymes (Lee et 
al., 2007; Stephens et al., 2007).  
 Both the mitochondrial and cytoplasmic FAS pathways of T. brucei are 
essential for parasite growth. In both PF and BF parasites, reduction of ACP by 
RNAi or conditional knockout resulted in reduced mitochondrial FAS and slowed 
parasite growth in culture (Stephens et al., 2007). T. brucei exhibits a condition 
and stage-specific requirement for cytoplasmic FAS. Reduction of enoyl-CoA 
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reductase by conditional knockout caused a growth phenotype only when PF 
parasites were cultured in low-lipid media (Lee et al., 2006). This is not the case 
in BF parasites; enoyl-CoA reductase was essential for growth in normal media 
and in a mouse model (Soo Hee Lee, personal communication).  
ACETYL-COA CARBOXYLASE 
FAS requires a substantial amount of malonyl-CoA, as it donates two 
carbons to the growing acyl-chain. Malonyl-CoA is generated by the 
carboxylation of acetyl-CoA, a reaction catalyzed by acetyl-CoA carboxylase 
(ACC). This is an ATP dependent reaction and therefore, is considered the first 
committed step in FAS (Barber et al., 2005).  
The T. brucei genome codes for a single ACC gene, which was 
determined by homology to other ACCs (Aslett et al., 2010; TbGeneDB). TbACC 
is a large multidomain enzyme, consisting of biotin carboxylase, biotin-carboxyl 
carrier protein (BCCP), and carboxyl-transferase (CT) domains. The ACC 
reaction proceeds forward in two steps. First, the carboxylation of the biotin 
prosthetic group proceeds by adding a CO2 group from a bicarbonate molecule. 
This is followed by the carboxyl transfer step, combining CO2 and acetyl-CoA, 
resulting in the creation of the two-carbon donor malonyl-CoA (Lee et al., 2008). 
Regulation of Acetyl-CoA Carboxylase 
The enzymatic activity of ACC is controlled by multiple post-translational 
modifications. Reversible phosphorylation is the best understood mechanism and 
is conserved in all described ACCs (Barber et al., 2005). Increased 
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phosphorylation causes a reduction in ACC activity. Both AMP-activated protein 
kinase (AMPK) and protein kinase A phosphorylate ACC and have direct impact 
on activity (Barber et al., 2005; Brownsey et al., 2006). Regulation of TbACC by 
phosphorylation has yet to be demonstrated. However, experiments in our lab 
have demonstrated that TbACC is indeed phosphorylated (Sunayan Ray, 
personal communication).   
Regulation of ACC activity by polymerization has also been reported.  In 
its basal state ACC exists as a dimer, but it is also capable of forming higher 
order polymers (Kleinschmidt et al., 1969; Mackall et al., 1978; Thampy et al., 
1985; Barber et al., 2005). in vitro treatment of chicken liver extracts with 
supraphysiological concentrations of citrate causes the enzyme to polymerize 
into long filaments and increases enzymatic activity (Beaty et al., 1985). In 
mouse liver the polymerization process is facilitated by the MIG12 protein. The 
presence of MIG12 lowers the citrate concentration needed to induce ACC 
polymerization and elevated activity (Kim et al., 2010). These filamentous 
polymers dissociate in response to ACC’s product, malonyl-CoA (Beaty et al., 
1983). ACC polymers in the form of planar arrays have also been reported in 
yeast and are believed to be active polymers (Schneiter et al., 1996). 
Mammalian Acetyl-CoA Carboxylase 
The mammalian genome contains two ACCs: ACC1 and ACC2. While 
both catalyze the conversion of acetyl-CoA to malonyl-CoA, their products serve 
very different functions in the cell. ACC1 is predominately involved in creating 
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malonyl-CoA to be used in fatty acid synthesis, while the malonyl-CoA produced 
by ACC2 is involved in regulating cellular energy usage. Malonyl-CoA is an 
allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1), the enzyme 
responsible for transporting long-chain fatty acids (LCFA) into the mitochondrion 
(Harada et al., 2007). By inhibiting CPT1, high malonyl-CoA concentrations 
reduce the rate of FA beta-oxidation within the mitochondrion. Low malonyl-CoA 
levels activate CPT1 and increase the amount of LCFA available to the beta-
oxidation pathway. By this mechanism cells avoids futile cycling, preventing 
simultaneous synthesis and oxidation of FA. This balance is believed to be 
regulated by AMPK. Activation of AMPK causes increased phosphorylation and 
inhibition of ACC (Bouzakri et al., 2008). 
Acetyl-CoA Carboxylase Inhibitors 
 As a consequence of the huge cost associated with the development of 
pharmaceuticals and the dire economic status of sub-Saharan Africa, critics 
contend that even the identification of a perfect drug target would not result in a 
commercially available therapy for African trypanosome infections. African 
trypanosomiasis and similar infectious diseases are very low priorities for 
pharmaceutical companies, so called “orphan diseases.” However, recent 
research has implicated the human ACC pathway as playing a role in diabetes, 
obesity, and some cancers, effectively sparking the interest of drug companies 
(Lopaschuk et al., 2006; Tong et al., 2006; Choi et al., 2007; Folmes et al., 2007). 
As a result, multiple drugs targeting human ACC are in the drug development 
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pipeline, and many of their analogs have been synthesized in the process 
(Cheng et al., 2006; Corbett et al., 2007). These compounds have the potential to 
inhibit TbACC, thereby reducing the problem of African trypanosomiasis being an 
“unprofitable” disease.        
In addition to its potential use as a drug target for human disease, ACC 
has long been recognized as a valuable target for chemical intervention in crop 
management and fungicides. Current allosteric ACC inhibitors can be divided into 
three distinct classes (Tong et al., 2006). 
Class 1 inhibitors work by preventing transfer of the carboxyl group 
from the BCCP domain to the acetyl-CoA substrate. The cyclohexanediones and 
aryloxyphenoxypropionates, also known as DIMs and FOPs, are members of this 
class. Haloxyfop targets the plastid ACCs of grasses by binding the CT domain 
and causing conformational changes that render the enzyme inactive (Delye et 
al., 2003; Zhang et al., 2004b; Xiang et al., 2009). Another class 1 inhibitor, 5-
(tetradecyloxy)-2-furancarboxylic acid (TOFA) accomplishes the same goal by a 
different mechanism. Upon entering the cell, TOFA is converted to a CoA 
thioester and competes for the acetyl-CoA binding pocket (Halvorson et al., 
1984; Tong et al., 2006).  
Class 2 inhibitors are substituted bipiperidylcarboxamides. CP-640186 
is the best characterized of the class 2 inhibitors. It interacts with ACC near the 
BCCP domain and interferes with the biotin moiety (Zhang et al., 2004a). 
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 Class 3 inhibitors are polyketide fungicides. Soraphen A is the best 
characterized class 3 compound. It binds ACC near the ATP binding pocket and 
interferes with the carboxylation of the biotin moiety by preventing the 
dimerization of the BC domain (Shen et al., 2004; Tong et al., 2006).  
 Many other naturally occurring products are also being explored as 
inhibitory molecules. They are attractive because they are readily available and 
many are currently approved for human consumption. The green tea catechin 
(−)-epigallocatechin-3-gallate (EGCG) inhibits ACC activity in a non-allosteric 
manner. EGCG activates AMPK and thereby increases ACC phosphorylation, 
resulting in decreased ACC activity (Moon et al., 2007a; Moon et al., 2007b; 
Huang et al., 2009). 
In the third and fourth chapters of this dissertation I demonstrate the 
effectiveness of haloxyfop and EGCG as TbACC inhibitors. Both molecules are 
commercially available and have well-characterized modes of action, making 
them useful tools in my efforts to characterize TbACC. These studies add to my 
initial characterization of TbACC (Chapter 2) and build upon previously published 
studies of haloxyfop and EGCG in related protozoan parasites. Taken together 
the experiments described in Chapters 2-4 significantly extend our knowledge of 
T. brucei FAS.  
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EXTRACELLULAR LIPID UPTAKE 
Mammalian lipid acquisition mechanisms can vary by tissue and cell type. 
In this section I will present a generalized review of the best-characterized 
mechanisms of lipid uptake. 
A primary route of lipid acquisition is through endocytosis of lipoproteins. 
Lipoproteins are made up of a polar surface layer, containing phospholipids, 
apolipoproteins, and cholesterol and a nonpolar inner core that contains 
triglycerides and cholesterol esters (Wasan et al., 2008). Lipoproteins are 
internalized by endocytosis and transported to the lysosome, where the 
components are liberated. In addition to bulk uptake of lipoproteins, specific 
phospholipids can be acquired from donor lipoprotein particles and inserted 
directly into the cell membrane (Engelmann et al., 2010). 
  A second major mechanism of lipid acquisition is through uptake of FAs. 
FAs have very low aqueous solubility, and therefore are usually associated with 
membranes or proteins, typically albumin in the mammalian bloodstream. To 
become internalized, FAs must first dissociate from albumin and partition into the 
outer leaflet of the phospholipid bilayer. This is followed by a flip-flop that 
changes the orientation of the FA carboxyl head group from the outer to the inner 
lipid-water interface. The FAs can then partition into the cell and become bound, 
activated, or incorporated into more complex lipid species (Glatz et al., 2010). 
This process follows biphasic kinetics. Partitioning into the lipid bilayer occurs 
quickly, but internalization is much slower (Mellors et al., 1989). The flip-flop 
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mechanism is widely considered the rate-limiting step in the uptake process 
(Kampf et al., 2007a; Kampf et al., 2007b).  
Uptake of FA is known to occur both by protein-mediated active transport 
and passive diffusion (Glatz et al., 2010). Fatty acid transport protein 1 (FATP1) 
is localized to the cellular membrane and actively moves fatty acids into the cell. 
Other proteins, such as CD36 and the peripheral membrane fatty acid binding 
protein, function by facilitating diffusion, binding FAs, and concentrating them on 
membrane surface. Bound fatty acids are more easily partitioned into the 
membrane than albumin-associated FAs, thus uptake rates are greatly 
increased.  
Lipid rafts, specifically caveolae, also appear to play a role in the FA 
uptake process. Caviolin exhibits high-affinity FA binding. However, its major role 
in FA uptake is to provide a plasma membrane docking site for CD36. CD36 is 
predominantly localized to caveolae but is dispersed throughout the plasma 
membrane when lipid rafts are disrupted by cholesterol depletion. This 
mislocalization is accompanied by a reduction in FA uptake (Ehehalt et al., 2006; 
Glatz et al., 2010). 
Non-plasma membrane associated proteins also play a role in the uptake 
of fatty acids. Before an internalized FA can be broken down for energy or 
incorporated into a more complex lipid species, it must first be activated. The 
activation process involves esterification to CoA by a family of enzymes called 
acyl-CoA synthetases (ACS). Before a FA is activated or bound by a protein, it 
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can leave the cell by outward passive diffusion. Esterification to CoA makes the 
resulting acyl-CoA membrane-impermeant. Thus, ACS increases retention of 
FAs that are internalized by facilitated or passive diffusion (Milger et al., 2006).  
Lipid Uptake in Trypanosoma brucei 
Multiple mechanisms for lipid uptake have been described in T. brucei. In 
the mammalian bloodstream the parasite can take up both high and low density 
lipoproteins via endocytosis (Coppens et al., 1995; Green et al., 2003). This 
process is enhanced by a lipoprotein scavenger receptor (Green et al., 2003; 
Thomson et al., 2009). PF T. brucei also likely utilizes a similar mechanism to 
take up lipophorin (LP) from the tsetse hemolymph. Uptake of LP has been 
demonstrated in the related parasite, Trypanosoma rangeli (Folly et al., 2003) 
and the malaria parasite, Plasmodium gallinaceum (Atella et al., 2009). In 
addition to endocytosis of lipoproteins, T. brucei has a specialized mechanism for 
acquisition of phospholipids. This process involves the coordinated activity of 
three proteins and has been validated in vitro for uptake of 
lysophosphatidylcholine (Bowes et al., 1993).   
To date little is known about the mechanisms of FA uptake in T. brucei. 
Proteins involved in uptake of FAs in T. brucei have not yet been identified and 
characterized. Early studies demonstrate that FA uptake follows similar biphasic 
kinetics as described in humans (Voorheis,1980). This similarity in kinetics 
suggests that, like in human FA uptake, both protein-mediated active transport 
and passive diffusion are likely occurring. The T. brucei genome does contain 5 
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ACSs, and some early characterization of the genes has been completed (Jiang 
et al., 2000; Jiang et al., 2001; Jiang et al., 2004). However, characterization of 
the enzymes in intact cells has not been previously undertaken. In Chapter 5 of 
this dissertation, I present the first experiments examining the role of the TbACS 
genes in T. brucei FA uptake and growth.  
  Additionally, because FA uptake likely plays a key role in the growth and 
virulence of the parasite, I performed an RNAi library screen to identify novel 
genes involved in this process. In Chapter 6 of this dissertation I describe the 
screen and provide suggestions for improvements.   
RNA INTERFERENCE IN Trypanosoma brucei  
A number of genetic tools are available for use in T. brucei. The initial 
description of RNAi in Caenorhabditis elegans (Fire et al., 1998) was followed 
quickly by its discovery in T. brucei (Ngo et al., 1998). Soon after, a number of 
genetic tools were developed to take advantage of the parasite’s RNAi 
machinery to study the function of genes in forward and reverse genetic 
experiments (Shi et al., 2000; Wang et al., 2000; LaCount et al., 2002; Morris et 
al., 2002). The last decade has seen a steady increase in the use of RNAi as a 
substitute for traditional knockouts or dominant negative mutants.  
The popularity of RNAi over traditional gene knockouts can be attributed 
to a number of factors. First, compared to creating deletion mutants through gene 
knockouts, RNAi is quick and less labor intensive. Specifically, creating an RNAi 
mutant involves a single cloning reaction and one stable transfection, whereas 
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creating knockouts requires multiple rounds of cloning and transfection, due to 
the diploid genome of T. brucei.   
Second, RNAi provides researchers a tool to study essential genes 
(Motyka et al., 2004; Balana-Fouce et al., 2007). With the exception of low-level 
leaky expression, uninduced RNAi mutants have identical gene expression to 
their parental cell lines. Induction of RNAi is achieved by addition of tetracycline 
to the growth media, initiating synthesis of dsRNA and degradation of target 
mRNA. The resulting phenotype can be effectively studied prior to the death of 
the cell. Deletion of essential genes is not possible because it results in death of 
the organism. An alternative approach, termed conditional knockout, involves 
stably transfecting an ectopic gene copy prior to native gene deletion. Conditional 
knockouts are even more labor intensive, and high ectopic gene expression 
levels can become toxic to the cell.  
 While RNAi has proven to be a very powerful tool, it comes with its own 
set of drawbacks. RNAi does not necessarily provide complete abolishment of 
the target protein. Even when mRNA is degraded below the level of detection, 
stable proteins can persist for the duration of an experiment. The level of protein 
required for parasite growth or function of a metabolic pathway can vary widely 
between genes and growth conditions (Krieger et al., 2000; Albert et al., 2005; 
Caceres et al., 2010; Vigueira et al., 2011). Thus, RNAi may provide insufficient 
knockdown to yield phenotypes for some genes. In these cases, alternative 
strategies such as knockout, dominant negative, or transposon mutagenesis 
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would need to be employed. A second limiting factor of RNAi is the rather rapid 
reversion of mutants upon induction. Knockdown of essential genes, resulting in 
death of the parasite, can promote selection for individuals that have mutated or 
deleted the RNAi vector thereby rendering it nonfunctional (Motyka et al., 2004). 
This phenomenon is most common in animal models, because drug selection for 
maintenance of the dsRNA expression system is no longer imposed on the 
parasite. 
The T. brucei RNAi system has proven to be a very useful tool in my 
research. I have utilized RNAi in reverse-genetics experiments to study the 
function of TbACC and TbACS (see Chapters 2, 5). I have also used an RNAi 
library (Morris et al., 2002) to perform a forward-genetics screen for genes 
involved in fatty acid uptake (see Chapter 6).  
In the future, I expect that the popularity of RNAi as a tool for research will 
continue to grow. Recently, an exciting publication described the creation of an 
efficient RNAi library in BF T. brucei (Alsford et al., 2011). This library was 
utilized to identify genes essential for BF parasite growth in vitro, an important 
first step in the development of new drug targets. In addition, great strides have 
been made towards the creation of an inducible RNAi system in a related 
trypanosome, Leishmania braziliensis (Lye et al., 2010). RNAi has been, and will 
continue to be a valuable weapon in our fight against trypanosome infections.   
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FIGURES 
Figure 1.1: T. brucei life cycle. T. brucei is transmitted between mammalian 
hosts by the blood-feeding tsetse fly. Figure adapted from Lee S.H., Stephens 
J.L., and Englund P.T. (2007) A fatty-acid synthesis mechanism specialized for 
parasitism. Nat Rev Microbiol 5: 287-297. 
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Figure 1.2: Enzymatic reactions of fatty acid synthesis by the T. brucei 
elongase pathway. Each cycle of four enzymatic reactions adds an additional 2 
carbons in length to the acyl-CoA product. Figure adapted from Lee S.H., 
Stephens J.L., and Englund P.T. (2007) A fatty-acid synthesis mechanism 
specialized for parasitism. Nat Rev Microbiol 5: 287-297. 
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CHAPTER TWO 
REQUIREMENT FOR ACETYL-COA CARBOXYLASE IN Trypanosoma brucei 
IS DEPENDENT UPON THE GROWTH ENVIRONMENT 
Patrick A. Vigueira and Kimberly S. Paul 
Department of Biological Sciences, Clemson University, Clemson, SC 
ABSTRACT 
Trypanosoma brucei, the causative agent of human African 
trypanosomiasis, possesses two fatty acid synthesis pathways: a major de novo 
synthesis pathway in the ER and a mitochondrial pathway. The 2-carbon donor 
for both pathways is malonyl-CoA, which is synthesized from acetyl-CoA by 
Acetyl-CoA Carboxylase (ACC). Here, we show that T. brucei ACC shares the 
same enzyme architecture and moderate ~30% identity with yeast and human 
ACCs. ACC is cytoplasmic and appears to be distributed throughout the cell in 
numerous puncta distinct from glycosomes and other organelles. ACC is active in 
both bloodstream and procyclic forms. Reduction of ACC activity by RNA 
interference (RNAi) resulted in a stage-specific phenotype. In procyclic forms, 
ACC RNAi resulted in 50-75% reduction in fatty acid elongation and a 64% 
reduction in growth in low lipid media. In bloodstream forms, ACC RNAi resulted 
in a minor 15% decrease in fatty acid elongation and no growth defect in culture, 
even in low lipid media. However, ACC RNAi did attenuate virulence in a mouse 
model of infection. Thus, the requirement for ACC in T. brucei is dependent upon 
the growth environment in two different life cycle stages. 
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INTRODUCTION 
 The deadly protozoan parasite Trypanosoma brucei, the causative agent 
of African sleeping sickness in humans and Nagana in livestock, is vectored by 
the bloodsucking tsetse fly and infects the blood and cerebrospinal fluid of its 
human and animal hosts. As it transits through its life cycle, the parasite 
encounters a number of different host microenvironments that differ in their 
availability of key nutrients such as proteins and lipids, including fatty acids. For 
example, there is a ~300X lower concentration of lipids in the cerebrospinal fluid 
compared to blood (Lentner, 1981). One important function of fatty acids in T. 
brucei is to anchor cell surface glycoproteins as part of their 
glycosylphosphatidylinositol (GPI) anchors. These cell surface glycoproteins play 
key roles in the parasite’s ability to evade host defenses. For example, switching 
of the GPI-anchored Variant Surface Glycoprotein (VSG) surface coat via 
antigenic variation protects T. brucei against immune attack in the mammalian 
bloodstream (reviewed in Morrison et al., 2009; Mansfield and Paulnock, 2005). 
Similarly, the GPI-anchored procyclin proteins may protect T. brucei against 
proteolytic attack in the tsetse midgut (Acosta-Serrano et al., 2001). The parasite 
has two ways to supply itself with fatty acids: acquire fatty acids from the host or 
synthesize its own fatty acids de novo (Smith and Bütikofer, 2010). There is a 
significant difference between the energy required for fatty acid uptake and 
synthesis: uptake of a 16-carbon fatty acid by passive diffusion would require 1 
ATP for activation to its CoA derivative, while synthesis of the same 16-carbon 
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fatty acyl CoA would require 6 ATPs and 12 reducing units (Lee et al., 2006). 
Thus, fatty acid uptake is likely preferred over the more energy intensive fatty 
acid synthesis pathway. However, when the host fatty acid supply is insufficient, 
the parasite must then synthesize its own fatty acids to meet its needs. 
 T. brucei has two fatty acid synthesis pathways: the fatty acid elongase 
pathway of the endoplasmic reticulum that serves as the major pathway for 
synthesis (Lee et al., 2006), and a minor pathway in the mitochondrion that 
catalyzes the synthesis of mitochondrial fatty acids (Stephens et al., 2007; Guler 
et al., 2008). T. brucei fatty acid elongation consists of a conserved cycle of 
reactions that starts with the condensation of the 2-carbon donor, malonyl-CoA, 
with an acyl-CoA primer (4–18 carbons long) followed by reduction, dehydration, 
and reduction steps to yield a fatty acyl chain that is two carbons longer. Malonyl-
CoA is synthesized from acetyl-CoA by Acetyl-CoA Carboxylase (ACC), a 
member of the biotin-dependent carboxylase family of enzymes (Jitrapakdee and 
Wallace, 2003). The ACC reaction is catalyzed in two steps: first, the ATP-
dependent carboxylation of the biotin prosthetic group, followed by transfer of the 
carboxyl group from biotin to the acceptor acetyl-CoA. Because the synthesis of 
malonyl-CoA requires the hydrolysis of ATP, the ACC reaction is considered the 
first committed step in fatty acid synthesis and is a well-documented control point 
for the regulation of this pathway in mammals and yeast (reviewed in Tehlivets et 
al., 2007; Saggerson, 2008). 
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 As T. brucei can acquire fatty acids from the host as well as synthesize 
them, the parasite likely has a mechanism to modulate its fatty acid synthesis 
pathway(s) in response to the environmental supply. Two published observations 
support this idea. First, bloodstream form T. brucei labeled with [3H]myristate 
(C14:0) in whole blood showed no elongation, but cells labeled in medium with 
only 5% serum lipids showed efficient elongatation of [3H]myristate into longer 
fatty acids (Doering et al., 1993). Second, T. brucei midgut procyclic forms grown 
in lipid-depleted medium had up-regulated the entire fatty acid elongase pathway 
compared to cells grown in normal medium (Lee et al., 2006). We propose that 
this ability to control fatty acid synthesis in response to the environment is critical 
to the process of host adaptation, allowing maximal usage of host resources to 
conserve energy that otherwise would be used for biosynthesis. To begin 
elucidating the mechanism(s) by which T. brucei fatty acid synthesis is regulated 
in response to the environment, we focused on ACC because it catalyzes the first 
committed step of fatty acid synthesis, is known to be highly regulated by multiple 
mechanisms in other systems, and could theoretically control flux through the 
fatty acid synthesis pathway via the availability of its key substrate, malonyl-CoA. 
 Here, we performed an initial characterization of T. brucei ACC. We show 
that ACC has a punctate cytoplasmic localization and that ACC is required by 
procyclic forms for growth in culture under lipid-limited conditions and by 
bloodstream forms for full virulence in mice. 
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RESULTS 
Comparison of T. brucei ACC to other ACCs 
 Alignment analysis revealed that the overall domain structure of T. brucei ACC is 
similar to eukaryotic-type multi-domain ACCs, with an N-terminal biotin 
carboxylase domain, a C-terminal carboxyltransferase domain, and a biotin 
carboxyl carrier domain sandwiched in the middle (Barber et al., 2005) (Fig. 2.1). 
Despite this conservation in overall enzyme architecture, T. brucei ACC shares 
limited overall identities of 31% and 33% with S. cerevisiae ACC and human 
ACC1, respectively, while human and yeast ACCs shared a slightly higher 44% 
identity (Fig. 2.2). Comparison of T. brucei ACC with ACCs from Trypanosoma 
cruzi and Leishmania major revealed a much higher degree of conservation 
among the trypanosomes, with 58% (Tb vs. Lm), 60% (Tc vs. Lm), and 66% (Tb 
vs. Tc) identities. As expected, overall sequence similarity was highest in the 
regions constituting the core of the biotin carboxylase domain, 
carboxyltransferase domain, and the residues surrounding the biotin attachment 
site (Fig. 2.2 and Fig. 2.3). Most of the residues shown by X-ray crystallography 
and/or mutational analysis to be involved in substrate binding and catalysis are 
conserved (see residues marked by asterisks in Fig. 2.2 and 2.3) (Thoden et al., 
2000; Zhang et al., 2003; Shen et al., 2004; Tong, 2005; Lee et al., 2008; Chou 
et al., 2009). In contrast, the large linker region between the biotin carboxyl 
carrier and the carboxyltransferase domains showed less conservation (Fig. 2.2 
and 2.3), presumably reflecting its primarily structural role. 
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 In addition, the predicted T. brucei ACC gene has a very short 7 amino 
acid N-terminal sequence prior to the first conserved residue of the biotin 
carboxylase domain, compared to that of S. cerevisiae ACC (36 amino acids) 
and the human ACC1 isoforms (17 - 132 amino acids) (Fig. 2.2; National Center 
for Biotechnology Information protein database). This short N-terminal sequence 
might be conserved in trypanosomatids, as the L. major ACC N-terminus 
appears to be equally truncated (Fig. 2.3). In most human ACC1 and ACC2 
variants, the N-terminal leader sequence contains a conserved serine (e.g. 
Ser117 in ACC1 isoform 1), which is a key site of post-transcriptional regulation 
by AMP-activated protein kinase (AMPK) (Barber et al., 2005). In contrast, the 
S. cerevisiae ACC N-terminus lacks this phosphorylation site and is instead 
regulated by SNF1/AMPK phosphorylation at other serine residues within the 
poorly conserved linker between the BCCP and CT domains (Fig. 2.1) (Woods et 
al., 1994; Shirra et al., 2001; Ficarro et al., 2002; Tehlivets et al., 2007). Like S. 
cerevisiae ACC, the T. brucei ACC N-terminal leader also lacks the conserved 
serine, and thus may be regulated at other sites or by distinct mechanisms from 
those controlling human ACC. 
ACC is expressed in both bloodstream and procyclic forms 
 The TriTrypDB indicates that the T. brucei genome encodes a single 
predicted ACC isoform (Tb927.8.7100) (Aslett et al., 2009), which was confirmed 
by Southern blotting (data not shown). Northern analysis of total mRNA revealed 
that the ACC mRNA is ~8.8 Kb and is transcribed in both bloodstream and 
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procyclic form life cycle stages (Fig. 2.4A). ACC (and other biotinylated proteins) 
can be detected on western blots using streptavidin conjugated to horseradish 
peroxidase (SA-HRP), which recognizes the biotin prosthetic group (Nikolau et 
al., 1985, Haneji and Koide, 1989). In addition to ACC, the T. brucei genome 
contains one other biotinylated protein: the 74 kD alpha subunit of 
3-methylcrotonyl-CoA carboxylase (Tb927.8.6970), which is a mitochondrial 
enzyme involved in amino acid degradation. SA-HRP blotting of bloodstream and 
procyclic form lysates revealed a predominant >200 kD band, roughly consistent 
with the predicted size of ACC (243 kD) (Fig. 2.4B and 2.5B) given the resolving 
power of the gel in this size range. The 74 kD alpha subunit of the 
3-methylcronotonyl-CoA carboxylase was not readily detected in total lysates, but 
could be detected in partially purified mitochondrial fractions (data not shown). 
Although additional cross-reacting bands become evident upon longer 
exposures, we show that the >200 kD band is specifically depleted upon ACC 
RNAi, as discussed below (Fig. 2.9B). Finally, ACC enzyme activity was detected 
in both bloodstream and procyclic form lysates and was dependent upon the 
addition of ATP and acetyl-CoA (Fig. 2.4C). Taken together, these data show 
that ACC is expressed and active in both life cycle stages. 
ACC is cytoplasmic and localized to numerous puncta 
 Multiple prediction algorithms (WoLF PSORT, TargetP/SignalP, and 
PredoTar) found no known targeting motifs in the ACC protein, predicting ACC to 
be cytosolic (Horton et al., 2007; Emanuelsson et al., 2007; Small et al., 2004). 
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To experimentally assess the localization of ACC, we used an epitope-tagging 
strategy to create a procyclic form cell line (PF ACC-myc) with a c-myc tag fused 
to the C-terminus of ACC. To minimize the possibility of mislocalizing the tagged 
protein due to over-expression of an ectopic copy, we tagged the genomic locus 
of only one ACC allele. Using immunoprecipitation with anti-c-myc antibody 
covalently linked to beads, we found that ACC-myc immunoprecipitates 
possessed ACC activity, while control immunoprecipitates from untagged cells 
were inactive (Fig. 2.5). This result indicates that the myc-tagged ACC allele 
encoded a functional enzyme. 
 First, we subjected lysates of PF ACC-myc cells to sub-cellular 
fractionation by differential centrifugation (see Fig. 2.6A for scheme) and 
analyzed the fractions by SDS-PAGE and western blotting (Fig. 2.6B). ACC-myc 
showed a fractionation pattern similar to the cytoplasmic marker HSP70, and 
distinct from the markers for the glycosome and ER. Moreover, the ACC-myc 
fractionation pattern was the same as that of native ACC in both PF ACC-myc 
cells (Fig. 2.6B) and wild-type procyclic cells (data not shown), indicating that the 
c-myc epitope was not affecting the localization of the tagged ACC.  
 Next, we examined the sub-cellular localization of ACC by 
immunofluorescence microscopy. ACC-myc was not uniformly distributed in the 
cytoplasm, but instead localized to a multitude of small distinct puncta (Fig. 2.7 
and 2.8, panels B, D, J, N, R, and V). Wild-type cells had no visible fluorescent 
signal at the same exposure time (Fig. 2.8, panels F and H) and only a faint haze 
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with an exposure 3.5 times longer (data not shown). A field of cells captured at a 
lower magnification demonstrated that specific labeling with the anti-c-myc 
antibody was reflected in the whole cell population (Fig. 2.8, panels C, D, G, and 
H). The ACC puncta did not co-localize with markers for the cytoplasm 
(cytoplasmic HSP70), the glycosomes (pyruvate phosphate dikinase, aldolase, 
and glyceraldehyde phosphate dehydrogenase), the ER (BiP), or the 
mitochondrion (lipoamide dehydrogenase) (Fig. 2.8, panels M-P, I-L, Q-T, and U-
X, respectively). Furthermore, the distribution of ACC-myc is distinct from that of 
Nile Red-stained lipid droplets (Fig. 2.8, panels Y and Z), Golgi (Ho et al., 2006; 
Ramirez et al., 2008), and acidocalcisomes, which are larger and less numerous 
(de Jesus et al., 2010; Fang et al., 2007). 
RNA interference of ACC is efficient in both bloodstream and procyclic 
forms 
 Because our attempts to delete both alleles of ACC were unsuccessful, 
we chose to assess the functional role of ACC in T. brucei using the pZJM RNAi 
vector to induce knockdown of ACC mRNA in bloodstream and procyclic cells 
(Wang et al., 2000; Morris et al., 2001). Northern analysis of total RNA showed 
that induction of RNAi reduced ACC mRNA by 76% in bloodstream forms and 
85% in procyclic forms (Fig. 2.9A). Similar results were obtained with at least four 
independent clones (data not shown). Like others, we have observed that the 
ACC RNAi cells can undergo RNAi reversion (Chen et al., 2003; Motyka and 
Englund, 2004). By day 25, northern analysis showed that procyclic cells had 
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completely recovered expression of ACC mRNA, even though ACC dsRNA was 
still being produced (data not shown). SA-HRP blotting revealed the loss of ACC 
protein over 10 days of RNAi (Fig. 2.9B). A separate analysis of 4 independent 
inductions showed that four days of ACC RNAi reduced ACC protein by 91 ± 7% 
in both bloodstream and procyclic forms. Four days of ACC RNAi also 
significantly reduced ACC activity in lysates (Fig. 2.9C), with an 87 ± 1% and 90 
± 1% reduction in bloodstream and procyclic cells, respectively (Fig. 2.10A and 
B). Finally, ACC RNAi resulted in no growth inhibition in either bloodstream and 
procyclic cells (Fig. 2.9D), with doubling times of 8 h and 15 h, respectively 
(Fig. 2.10C). Fluorescence microscopy revealed that ACC RNAi resulted in no 
gross defects in cell morphology, or in the structure of the mitochondrion, ER, or 
nuclear/mitochondrial DNA as revealed by immunostaining with specific 
antibodies to a mitochondrial marker (lipoamide dehydrogenase), an ER marker 
(BiP), or by staining with the DNA intercalating dye DAPI (data not shown). 
Effect of ACC RNAi on overall lipid metabolism 
 To look for ACC RNAi-induced changes in fatty acid metabolism, ACC 
RNAi cells were incubated with [3H]laurate (C12:0) or [3H]myristate (C14:0), 
which can be elongated by the fatty acid elongase pathway and incorporated into 
lipids. Analysis of the labeled lipids by thin-layer chromatography (TLC) in the 
absence of RNAi showed labeling of neutral lipids at the top, free fatty acids co-
migrating with the free fatty acid marker, myristate (Myr), and various 
phospholipids co-migrating above and below the phospholipid marker, 
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phosphatidylcholine (PtdC) (Fig. 2.11A, lanes 1, 3, 5, and 7). Migrating below the 
phospholipids, we also observed labeling of the bloodstream form specific lipids, 
Glycolipids A and C (and their intermediates) (Buxbaum et al., 1994), which are 
precursors to the VSG GPI-anchor (Fig. 2.11A, lanes 5 and 7). In procyclic forms, 
ACC RNAi resulted in little change in the overall labeling patterns of [3H]laurate 
or [3H]myristate, except for an accumulation of free fatty acids and one of the 
phospholipids (indicated by asterisk; likely phosphatidylethanolamine based on 
its migration) (Fig. 2.11A, lanes 2 and 4). In bloodstream forms, ACC RNAi 
labeling resulted in no change in the species labeled by [3H]laurate (Fig. 2.11A, 
lanes 5 and 6). In contrast, ACC RNAi reduced incorporation of [3H]myristate into 
phospholipids (Fig. 2.11A, lanes 7 and 8), while no loss of labeling was observed 
in the bloodstream-specific Glycolipids A and C. 
ACC is required for elongation of fatty acids 
 We next examined the effect of ACC RNAi on the major pathway for fatty 
acid synthesis in T. brucei. Because the cell-free fatty acid elongation assay 
bypasses the ACC step (Morita et al., 2000b), we examined fatty acid elongation 
in vivo. Cells labeled with [3H]laurate (C12:0) and [3H]myristate (C14:0), which 
should be converted to longer fatty acids if the elongase pathway is functioning 
(Lee et al., 2006), were analyzed for elongation products using reverse-phase 
TLC. In uninduced procyclic forms, both [3H]laurate and [3H]myristate were 
elongated to products up to 18 carbons (Fig. 2.11B, lanes 1 and 3). ACC RNAi in 
procyclics resulted in a 74 ± 6% and 53 ± 5% inhibition of [3H]laurate and 
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[3H]myristate elongation, respectively (Fig. 2.11B, lanes 2 and 4). Uninduced 
bloodstream forms readily elongated [3H]laurate (Fig. 2.11B, lane 5), but little 
[3H]myristate elongation occurred (Fig. 2.11B, lane 7). ACC RNAi in bloodstream 
forms resulted in a 15 ± 5% inhibition of [3H]laurate elongation (Fig. 2.11B, lane 
6), and completely abolished the minor elongation that occurred with 
[3H]myristate (Fig. 2.11B, lane 8). 
Effect of ACC RNAi on growth in low-lipid media 
 Even though ACC RNAi reduced elongase activity, the cells were still able 
to grow normally in culture (Fig. 2.9D). Because T. brucei can also readily 
acquire fatty acids from the medium (Dixon et al., 1971; Voorheis, 1980; Bowes 
et al., 1993; Lee et al., 1999; Coppens et al., 1995), we assessed the growth of 
ACC RNAi cells in low lipid media. ACC RNAi in bloodstream forms still showed 
no effect on growth in two different formulations of low lipid medium compared to 
the uninduced control (Fig. 2.12A). In contrast, ACC RNAi in procyclic forms 
reduced growth by 64% in low lipid medium (Fig. 2.12B). Furthermore, 68% of 
this growth defect could be reversed by the addition of 35 µM stearate (C18:0), 
suggesting that the growth defect arose from a lack of fatty acids rather than 
some other limiting factor in the medium. Finally, pre-adaptation of bloodstream 
and procyclic cells by growth in low lipid media for 10 days prior to induction of 
ACC RNAi did not enhance the effect of ACC RNAi on growth (Fig. 2.13). 
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ACC is required for full virulence in mice 
 To assess the virulence of ACC RNAi cells, NIH Swiss mice (n=10 per 
group) were either left untreated (uninduced control) or treated with doxycycline 
(a bioavailable tetracycline analog) in their drinking water to induce ACC RNAi. 
Mice were then infected intra-peritoneally with 1 x 105 freshly thawed 
bloodstream form ACC RNAi trypanosomes. The uninduced control infection 
resulted in a mean time-to-death of 12.7 days by Kaplan-Meier survival analysis 
(Fig. 2.14). However, when ACC RNAi was induced in the doxycycline-treated 
mice, the mean time-to-death was significantly increased to 22.3 days (p = 
0.0021, Wilcoxon test).  
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DISCUSSION 
 Among the protozoa, only the ACCs of the Apicomplexan parasites 
Toxoplasma gondii and Plasmodium falciparum have been characterized. These 
Apicomplexans possess two eukaryotic-type multi-domain ACC isozymes: a 
plastid ACC1 that functions in plastid de novo fatty acid synthesis and a cytosolic 
ACC2, with proposed functions in fatty acid elongation, polyketide synthesis, and 
mitochondrial fatty acid synthesis (Zuther et al., 1999; Jelenska et al., 2001; 
Gardner et al., 2002; Waller et al., 2003; Mazumdar and Striepen, 2007). Here, 
we have performed the first characterization of the sole trypanosome ACC 
isozyme in bloodstream and procyclic forms and explored its role in fatty acid 
metabolism. 
 The cytosolic punctate distribution of ACC-myc in T. brucei has not been 
observed previously in other eukaryotes and thus, appears to be novel. What are 
these puncta? They could represent a fixation artifact from the paraformaldehye. 
However, ACC-myc showed the same punctate pattern when cells were fixed in 
cold methanol, suggesting this is not the case (data not shown). The puncta 
could also represent non-specific aggregation due to the c-myc epitope tag. Four 
reasons argue against this: first, ACC-myc showed the same fractionation pattern 
as native ACC, suggesting that the myc tag has no significant effect upon the 
sub-cellular distribution of ACC; second, ACC-myc immunoprecipitates possess 
ACC activity, suggesting that the myc tag did not affect enzyme function; third, 
because the myc tag was incorporated into the genomic locus, ACC-myc is likely 
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expressed at endogenous levels rather than at the high levels associated with 
epitope-tag artifacts; fourth, one previous report of a cytosolic myc-tagged protein 
showed diffuse staining in T. brucei rather than the puncta we observe for ACC 
(Peterson et al., 1997). 
 An intriguing alternative is that these puncta might represent polymerization 
of ACC in T. brucei. Mammalian and avian ACCs polymerize into filaments 
(Kleinschmidt et al., 1969; Mackall et al., 1978), and there is evidence suggesting 
yeast ACC may also polymerize (Schneiter et al., 1996). In birds and mammals, 
ACC polymerization is dynamic and the polymer form is the active form (Ashcraft 
et al., 1980; Beaty and Lane, 1983; Beaty and Lane, 1985; Thampy and Wakil, 
1988; Kim et al., 2010). Whether they are non-specific aggregates or polymers, 
the nature of the ACC puncta must be independently confirmed using an 
alternative epitope tag or an antibody to native T. brucei ACC before their 
function can begin to be explored.  
 Among unicellular eukaryotes, ACC has been most extensively 
characterized in the yeasts. In both S. cerevisiae and Schizosaccharomyces 
pombe, deletion of ACC is lethal (Hasslacher et al., 1993; Saitoh et al., 1996), 
while a reduction in ACC activity leads to growth inhibition and a range of defects 
in nuclear and vacuolar membrane function (Saitoh et al., 1996; Schneiter et al., 
1996; Schneiter et al., 2000). Thus, we predicted that ACC RNAi would reduce 
overall lipid biosynthesis activity, resulting in growth inhibition in T. brucei. 
Instead, we found that bloodstream form and procyclic cells differed in the effect 
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of ACC RNAi upon fatty acid elongation and growth in culture. We also found that 
the effect of ACC RNAi was dependent upon the growth environment. 
 Based on our results, we propose that procyclic form T. brucei is 
dependent upon ACC only when environmental lipids are limiting. It is well known 
that T. brucei can readily take up and use lipids from their environment (Dixon et 
al., 1971; Voorheis, 1980; Bowes et al., 1993; Lee et al., 1999; Coppens et al., 
1995). Thus, in normal medium, procyclic cells primarily rely on fatty acid uptake 
to satisfy their needs, rather than de novo synthesis. Therefore, reduction of fatty 
acid elongation upon ACC RNAi had a limited effect on overall lipid metabolism 
because the cells were already relying upon exogenous lipids. In low lipid 
medium, however, the procyclics require ACC and fatty acid elongation to 
compensate for the fatty acid deficit. Under these conditions, reduction of ACC 
activity and fatty acid elongation rendered the cells unable to grow efficiently. 
This growth defect of procyclic ACC RNAi cells in low lipid conditions is very 
similar to that seen with RNAi of the enoyl-CoA reductase in the fatty acid 
elongation pathway (Lee et al., 2006), consistent with the coupling of these 
enzymes into the same metabolic pathway. 
 In bloodstream forms, the response to ACC RNAi differed significantly 
from procyclic forms. Despite efficient knockdown of ACC activity, fatty acid 
elongation was only moderately reduced, and the cells exhibited no growth 
defect in either normal or low lipid media. This suggests that in cultured 
bloodstream forms, the fatty acid elongation pathway may not be very dependent 
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upon ACC. This result was unexpected for two reasons: first, in all other 
eukaryotes examined to date, fatty acid synthesis and elongation are dependent 
upon malonyl-CoA supplied by ACC; second, bloodstream form cells have a high 
demand for myristate to anchor their VSG surface coat, which is a relatively 
scarce fatty acid in serum and scarcer still in standard culture medium (Paul et 
al., 2001). One possible explanation is that the residual ~10% ACC activity 
supports sufficient fatty acid elongation. If true, this suggests that the level of 
ACC expression in bloodstream forms is at >10-fold excess over what is required 
for growth in culture. Other metabolic enzymes, such as trypanothione reductase 
(Krieger et al., 2000) and several glycolytic enzymes (Albert et al., 2005; Caceres 
et al., 2010), have been reported to be present in excess, though a 75-90% 
knockdown of these enzymes did cause an observable growth defect. 
 In contrast to procyclics, loss of ACC had little apparent impact upon 
bloodstream forms in culture, except one notable effect upon the metabolism of 
[3H]myristate. As previously reported (Doering et al., 1993; Morita et al., 2000b), 
very little elongation of [3H]myristate occurs in bloodstream forms, likely resulting 
from the exclusive use of myristate as the fatty acid moiety in the VSG GPI-
anchors (Ferguson et al., 1988). However, under ACC RNAi conditions, we 
observed a general loss in the incorporation of [3H]myristate into phospholipids, 
while incorporation into the VSG GPI anchor precursors, Glycolipids A and C was 
preserved. Thus, ACC RNAi revealed a partitioning of the myristate pool, where 
the myristoylation of the GPI anchors takes priority over incorporation into 
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phospholipids. This phenomenon has been observed previously (Doering et al., 
1993; Morita et al., 2000b), and highlights the special importance of myristate in 
bloodstream form T. brucei. Morita et al. reported that myristate produced by the 
ELO pathway was preferentially incorporated into the VSG GPI anchors. Here, 
we show that exogenous myristate is likewise preferentially incorporated into the 
VSG GPI anchors, perhaps by special delivery from acyl-CoA binding protein 
(Milne and Ferguson, 2000), or by one or more acyl-CoA synthetases, four of 
which can efficiently activate myristate to myristoyl-CoA (Jiang and Englund, 
2001). 
 Low levels of ACC were sufficient for growth of bloodstream forms in 
culture, even in low lipid media where the fatty acid elongase pathway is known 
to be up-regulated (Lee et al., 2006). Yet ACC RNAi led to decreased virulence 
in a mouse model of infection. One major difference between in vitro culture and 
growth in the animal host is the presence of the host’s immune system. Thus, 
one likely explanation for the reduced virulence is that ACC RNAi reduced the 
ability of the parasite to evade the immune system. The primary means of T. 
brucei to avoid the host’s adaptive immune system is antigenic variation, in which 
a “new” VSG variant is trafficked to the surface while the “old” VSG variant is 
either shed from the cell surface or internalized and degraded (Seyfang et al., 
1990; Mansfield and Paulnock, 2005). Furthermore, VSG itself is constantly 
recycling off and back on to the cell surface via coupled endocytosis/exocytosis 
(Engstler et al., 2004). Perhaps the ACC RNAi cells are compromised in their 
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ability to maintain their VSG coat due to problems in trafficking and/or recycling. 
This phenomenon has been observed previously for conditional knockouts of 
phosphatidylinositol synthase and neutral sphingomyelinase (Young and Smith, 
2010; Martin and Smith, 2006). 
 Another important immune evasion strategy of T. brucei is the 
endocytosis-mediated clearance of antibodies bound to the surface of the 
parasite (Schwede and Carrington, 2010). Under immune pressure, T. brucei 
dramatically increases its endocytic activity in order to clear complement-
activating surface immune complexes (Balber et al., 1979; Russo et al., 1993; 
O'Beirne et al., 1998; Engstler et al., 2007; Natesan et al., 2007). Thus, the ACC 
RNAi cells may be unable to meet the increased demand in lipid synthesis 
arising from the dramatic upregulation in membrane turnover in the animal host. 
The resulting failure to adequately clear surface antibody complexes would then 
lead to reduced virulence. 
 Although the survival of the mice was increased under ACC RNAi 
induction, the mice were unable to clear the infection and ultimately, nearly all 
succumbed. The mice’s inability to clear the infection is likely due to the 
emergence of RNAi revertants through positive selection and the fact that 
antibiotic selection of the transgenes necessary for RNAi (T7 polymerase and Tet 
repressor) was not maintained during infection to avoid drug toxicity (Lecordier et 
al., 2005; Jetton et al., 2009). Supporting this idea, trypanosomes isolated from 
an induced mouse late in infection (~107 parasites/ml) were shown to be 
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expressing ACC protein by SA-HRP blotting, though the level of ACC detected 
was less than that in trypanosomes isolated from a control uninduced mouse 
(data not shown). 
 This work extends our understanding of fatty acid synthesis in T. brucei 
and points to the importance of exogenous sources of fatty acids in the overall 
lipid metabolism of these parasites. Finally our data raise key questions about 
how T. brucei senses environmental fatty acids and transduces this information 
into regulatory decisions governing its fatty acid metabolism. Such processes are 
key to survival, enabling the parasite to adapt its fatty acid metabolism to each 
host environment to satisfy its lipid needs while minimizing wasteful energy 
expenditure. 
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MATERIALS AND METHODS 
Reagents 
 All chemicals and reagents were purchased from Thermo Fisher Scientific 
and Sigma except: Minimum Essential Medium Eagle (MEM), Iscove’s Modified 
Dulbecco’s Medium (IMDM), 4’-6-diamidino-2-phenylindole (DAPI) (Invitrogen), 
Serum Plus (JRH Biosciences), delipidated fetal bovine serum (FBS) (Cocalico 
Biologicals), poly-L-lysine solution and normal goat serum (Electron Microscopy 
Sciences). [α-32P]dATP (Perkin-Elmer), and [14C]NaHCO3, and [3H]-labeled fatty 
acids (American Radiolabeled Chemicals). The mouse monoclonal 9E10 anti-c-
myc antibody was from Santa Cruz Biotechnology. The rabbit polyclonal 
antibodies to BiP and cytoplasmic HSP70 were generously provided by Dr. Jay 
Bangs (University of Wisconsin-Madison) (Bangs et al., 1993; McDowell et al., 
1998). The rabbit polyclonal anti-lipoamide dehydrogenase antibody was a kind 
gift of Dr. Luise Krauth-Siegel (University of Heidelberg) (Schoneck et al., 1997). 
The rabbit polyclonal 2841D anti-glycosome antibody was a generous gift from 
Dr. Marilyn Parsons (Seattle Biomedical Research Institute) (Parker et al., 1995) 
and recognizes three glycosomal enzymes: Pyruvate Phosphate Dikinase 
(PPDK) (~100 kD), Aldolase (~41 kD), and Glyceraldehyde Phosphate 
Dehydrogenase (GAPDH) (~39 kD). 
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Trypanosome Strains and Cell Lines 
Wild-type procyclic and bloodstream form T. brucei strain 427 were 
provided by Dr. Paul Englund (Johns Hopkins School of Medicine). Procyclic and 
bloodstream form T. brucei transgenic cell lines containing genomically-
integrated Tet repressor and T7 polymerase (29-13 and 90-13 respectively (Wirtz 
et al., 1999; Hirumi and Hirumi, 1989)) were generously provided by Dr. George 
Cross (Rockefeller University). Bloodstream form parasites were grown in HMI-9 
medium (Hirumi and Hirumi, 1989) containing 10% heat-inactivated FBS/10% 
Serum Plus and supplemented with 2.5 µg/ml G418, 5 µg/ml hygromycin, and 
2.5 µg/ml phleomycin, as needed. Procyclic form parasites were grown in SDM-
79 medium (Brun and Shonenberger, 1979) containing 10% heat-inactivated 
FBS and supplemented with 15 µg/ml G418, 50 µg/ml hygromycin, and 2.5 µg/ml 
phleomycin, as needed. 
Preparation of Low-Lipid Media 
The only source of lipids in media comes from the serum additives. 
According to the manufacturers, both Serum Plus and delipidated FBS contain 
~20% serum lipids. Two types of low-lipid HMI-9 media were prepared. 
Delipidated medium (DL) was prepared with 10% Serum Plus and 10% 
delipidated FBS. Serum Plus only medium (SP) was prepared with 10% Serum 
Plus only. Thus, the DL and SP media contain serum lipids equivalent to 4% and 
2% FBS, respectively, compared to 12% for normal HMI-9 medium. For procyclic 
cells, low-lipid DL medium was prepared with 10% delipidated FBS, and 
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contained serum lipids equivalent to 2% FBS, compared to 10% for normal SDM-
79. For fatty acid rescue experiments, a final concentration of 35 µM stearate 
(C18:0) was added to the medium. 
RNA Purification and Northern Analysis 
Total RNA was purified and northern analysis was performed as 
previously described (Wang et al., 2000), except 1 x 107 cell equivalents or 10-15 
µg of total RNA was loaded per lane and blots probed with a 32P-labeled DNA 
probe corresponding to the same ACC sequence used for ACC RNAi (see 
below). 
Preparation of Cell Lysates 
 Hypotonic lysates were prepared as described (Morita et al., 2000b). We 
also prepared lysates using an alternative method developed for 
radioimmunoprecipitation assays (RIPA): 1 x 108 cells were washed twice in 
BBSG (50 mM Bicine-Na+ pH 8, 50 mM NaCl, 5 mM KCl, 70 mM glucose) and 
the final cell pellet frozen on dry ice. The frozen pellet was overlaid with 100 µl 
TBS-RIPA buffer (1X Tris-Buffered Saline (TBS), 2 mM EDTA, 0.5 mM DTT, 1% 
(v/v) nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS) 
supplemented with 0.5 µg/ml leupeptin, 1 mM phenylmethanesulfonyl fluoride 
(PMSF), 0.1 mM Nα-p-tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK), 
2 µM pepstatin A and allowed to thaw on ice for 10 min. Cells were vortexed 
every 5 min for 30 min, with 20 sec of resting on ice between vortexing. Cell 
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lysates were centrifuged for 30 min at 4°C at 16,000 x g to remove cell debris. 
Supernatant was removed, aliquotted, snap frozen in liquid nitrogen, and stored 
at -80°C. 
Streptavidin Blotting 
For streptavidin-blotting, lysates were fractionated on 8% SDS-PAGE 
gels, transferred to nitrocellulose, and blocked in Wash Buffer (1% dry milk, 1X 
TBS, 0.05% Tween-20). Blots were probed for ACC with streptavidin-horseradish 
peroxidase conjugate (SA-HRP) (Pierce) diluted 1:200 in Streptavidin Wash 
Buffer (0.2% dry milk, 1X TBS, 0.05% Tween-20). Blots were washed 4X in 
Streptavidin Wash Buffer, followed by 2 washes in 1X TBS/0.05% Tween-20. 
The blots were developed using the Pico SuperSignal Enhanced 
Chemiluminescence kit (Pierce), and exposed to HyBlot CL film (Denville). For 
some experiments the blot was cut, and the top half probed for ACC with SA-
HRP as above, while the bottom half was probed for tubulin as follows. Blot was 
incubated with a mouse anti-tubulin antibody (clone B-5-1-2 ; Sigma) diluted 
1:500,000 in Wash Buffer, washed 4X in Wash Buffer, and probed with HRP-
conjugated goat anti-mouse IgG antibody (Invitrogen) diluted 1:20,000 in Wash 
Buffer. After 4 washes in Wash Buffer and 2 washes in 1X TBS, 0.05% Tween-
20, blots were developed for ECL. Semi-quantitative analysis of blots was 
performed using densitometry (NIH Image J software) of appropriately exposed 
films (unsaturated signal within the linear range of the film). 
 57
ACC Enzyme Activity 
To assay ACC activity, we modified a biotin carboxylase assay described 
previously (Wurtele and Nikolau, 1990). To remove endogenous CoA substrates, 
lysates were either dialyzed into BC Buffer (50 mM Tris-Cl pH 8, 5 mM MgCl2, 2 
mM DTT) for 4-12h at 4°C or alternatively, were desalted on a G50-80 sephadex 
column (Sigma) equilibrated in BC Buffer. Treated lysates were then incubated in 
a final volume of 100 µl BC Buffer supplemented with 5 mM ATP, 0.6 mM acetyl-
CoA, 1 mg/ml fatty acid free bovine serum albumin (BSA) (Sigma), and 2 mM 
[14C]NaHCO3 (14.9 mCi/mmol) for 30 min at 30°C, mixing every 10 min. 
Reactions were stopped by transferring tubes to ice for 5 min. Unreacted 
[14C]NaHCO3 was released as [14C]CO2 by the addition of 50 µl 6N HCl. Acid-
precipitated [14C]malonyl-CoA product was collected on Whatman #1 filter circles, 
air-dried, and quantified by scintillation counting. Linear regressions and Student 
t-Test analyses were performed using Microsoft Excel. 
Generation of ACC-myc Cell Line 
We used an in situ epitope-tagging strategy to generate a procyclic cell 
line with the C-terminus of one ACC allele fused to the c-myc epitope. We used 
PCR with bipartite primers and the appropriate plasmid template to generate a 
936 bp linear tagging construct (ACC-MYC/Phleo/ACC 3’-UTR) with the following 
features (in 5’-3’ order): 3’ end of ACC gene fused in-frame with c-myc epitope 
ending with stop codon, α/β tubulin intergenic region, phleomycin resistance 
gene, 5’ end of ACC 3’ UTR sequence. To make this construct we used a 2-step 
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PCR procedure. First, we used a forward primer comprised of the last 54 bp of 
the ACC gene (without stop codon) followed by 6 bp of the c-myc epitope 
(5’-GACGAAAGGATGCGGCGTGCGGCCATGCAGGCGCTGGAACGTACAACC
GCGAAGGGCCGCTCTGAGCAA-3’). The reverse primer sequence is 
comprised of 21 bp of the phleomycin resistance gene followed by the first 44 bp 
of the ACC 3’-UTR 
(5’-TAATTCTCATTCCTTGCCTCCAGTGGCGCCGCATCCCACGCCATGTCAG
TCCTGCTCCTCGGCCAC-3). For template DNA, we used the mycPHLEO 
plasmid (a generous gift of Dr. Meredith Morris, Clemson University), which 
contains the c-myc sequence, α/β tubulin intergenic region, and phleomycin 
resistance gene. The resulting amplicon encoding the linear tagging construct 
was cloned into the pCR 2.1-TOPO vector and sequenced. For the second PCR 
step, we used shorter forward and reverse primers that flank the linear tagging 
construct (5’-GACGAAAGGATGCGGCGT-3’, and 
5’-TAATTCTCATTCCTTGCCTCC-3’, respectively) to perform a large-scale PCR. 
The resulting amplicon (ACC-MYC/Phleo/ACC 3’-UTR) was purified using a 
MinElute column (Qiagen), and 15 µg of purified targeting construct was 
electroporated into 1 x 108 procyclic form 427 cells and selected in 2.5 µg/ml 
phleomycin. Integration of the tagging construct into the genomic locus via 
homologous recombination generated an in-frame fusion of the c-myc epitope to 
the 3’ end of one allele of ACC. Correct integration was confirmed by diagnostic 
PCR and western blotting. 
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Sub-Cellular Fractionation 
Hypotonic lysates of wild-type and ACC-myc-expressing procyclic form 
cells were subjected to differential centrifugation (Bangs et al., 1993; Roggy and 
Bangs, 1999). Briefly, lysate and then supernatants were fractionated by three 
successive centrifugation steps: a 1,000 x g step yielding P1 (cell fragments, 
nuclei, mitochondria) and S1 fractions; a 100,000 x g step yielding P2 
(microsomes) and S2 fractions; and a second 100,000 x g step yielding P3 
(residual microsomes) and S3 (cytosol) fractions (Fig. 2.6A). Samples of each 
sub-cellular fraction (1.5 x 106 cell equivalents) were separated by 10% SDS-
PAGE and transferred to nitrocellulose. Membranes were processed for 
streptavidin blotting as described above. To probe for ACC-myc or sub-cellular 
markers, membranes were blocked ≥ 1 h in 5% milk/1X TBS and probed with 
primary antibodies diluted in 5% milk/1X TBS/0.5% Tween-20 as follows: anti-
c-myc (clone 9E10), 1:250; anti-glycosome, 1:7,500; anti-cytosolic HSP70, 
1:4000; anti-BiP, 1:2000. HRP-conjugated goat anti-mouse or goat anti-rabbit 
secondary antibodies (Pierce) were diluted 1:10,000 in 5% milk/1X TBS/0.5% 
Tween-20. After washing, blots were developed using ECL and exposed to film 
as described above. 
Microscopy 
Microscopy was performed essentially as described in (Field et al., 2004). 
Briefly, wild-type and ACC-myc procyclic cells were harvested by centrifugation 
(800 x g, 10 min), washed once with ice-cold Voorheis’s modified PBS (vPBS) 
 60
(Nolan et al., 2000), and fixed on ice in 3% paraformaldehyde (w/v) in vPBS for 
1 h. Fixed parasites were adhered to poly-L-lysine treated glass slides and 
permeabilized for 10 min in 0.1% Triton X-100 (v/v) in vPBS. Slides were 
incubated in microscopy blocking solution (MBS: 0.5% bovine serum albumin 
(BSA) (w/v), 5% normal goat serum (v/v), 20% FBS (v/v) in vPBS) for ≥ 1 h. 
Primary antibodies were used at the following dilutions in MBS: 9E10 anti-C-myc, 
1:100; anti-glycosome, 1:100; anti-cytoplasmic HSP70, 1:1000; anti-BiP 1:1000 
(ER marker); and anti-lipoamide dehydrogenase 1:500 (mitochondrial marker). 
Secondary antibodies were goat anti-mouse and goat anti-rabbit conjugated to 
Alexa Fluor 488 (green) or Alexa Fluor 594 (red) (Invitrogen) diluted 1:750 in 
MBS. To stain lipid droplets, cells were incubated with 0.005% Nile Red diluted in 
vPBS (Greenspan et al., 1985; Robibaro et al., 2002). The broad emission 
spectra of Nile Red prevents the co-staining of lipid droplets and ACC-myc in the 
same cells (Wolinski and Kohlwein, 2008). Immediately prior to imaging, the 
nucleus and kinetoplast were stained with 4’,6-diamidino-2-phenylindole (DAPI) 
(1 mg/mL in vPBS) (Invitrogen) (Field et al., 2004). Images were collected using 
a Nikon TE2000 widefield epifluorescence microscope and image acquisition 
was performed using the Nikon NIS Elements software package. 
RNA Interference 
To make the ACC RNAi construct, a fragment bracketing the start codon 
of ACC (-110 to +467 nt) was amplified by PCR (Roche Expand High Fidelity) 
from wild-type procyclic form 427 genomic DNA using a forward primer 
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containing a 5’ Xho I site (5’-CCGctcgagTCCGAGCTCGCAAAGTG-3’) and a 
reverse primer containing a 5’ Hind III site 
(5’-CCCaagcttGTCGCCCAAAGCAAACATC-3’). This 572 bp amplicon was 
cloned first into pCR2.1 TOPO prior to sub-cloning into the tetracycline-inducible 
RNAi vector pZJM (Wang et al., 2000). The pZJM.ACC plasmid was confirmed 
by sequencing (one T-to-C difference from 927 sequence at nt -55). 
 Bloodstream and procyclic form RNAi cell lines were generated as 
described previously (Wang et al., 2000; Morris et al., 2001), with modifications 
suggested by J. Roper and M. Ferguson (pers. comm.). pZJM.ACC plasmid was 
linearized by Not I digestion and precipitated in ethanol to a final concentration of 
10 mg/ml. Prior to transfection, cells were washed twice in Cytomix (van den Hoff 
et al., 1992). For transfection into 29-13 procyclic cells, 100 µg of linearized 
pZJM.ACC was electroporated into 1 x 108 washed cells in a final volume of 0.5 
ml. A stable non-clonal procyclic ACC RNAi population was established first, 
followed by isolation of clonal cell lines by limiting dilution. For transfection into 
90-13 bloodstream form cells, 5 replicate transfections were prepared, each 
containing 100 µg linearized pZJM.ACC and 3 x 107 washed cells in a final 
volume of 0.5 ml. After electroporation, the 5 transfections were pooled and 
dispensed into 24 well plates, resulting in clonal cell lines. 
 For growth curves, ACC RNAi cells were diluted into normal or low-lipid 
media, induced for RNAi by the addition of tetracycline (1 µg/ml final) (Wang et 
al., 2000) and cell density monitored using either a Z1 dual-threshold Coulter 
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Counter (Beckman) or a FACScan flow cytometer (Becton Dickinson). For 
comparison purposes, the slopes of the growth curves (linear correlation 
coefficients) were derived from linear regressions performed using Microsoft 
Excel. Doubling times were calculated from the slopes. Student t-Test analysis 
was performed using Microsoft Excel. 
Metabolic Labeling and Lipid Analysis 
Metabolic labeling was performed essentially as described (Paul et al., 
2004). Briefly, after 7 days of RNAi induction, 1 x 108 cells were washed 3X in 
BBSG and resuspended in 1 ml of either HMI-9 (for bloodstream forms) or SDM-
79 (for procyclics). The 1 ml of cell suspension was then added to tubes 
containing 50 µCi of dried down [11,12-3H]laurate (C12:0; 50-60 mCi/mmol) or 
[9,10-3H]myristate (C14:0; 50-60 Ci/mmol) and incubated for 2 h in a 37°C 
(bloodstream forms) or 28°C (procyclic forms) CO2 incubator. Total lipids were 
extracted using a modified Folch method, equal DPMs were loaded per lane 
(4,000-10,000), and analyzed by normal phase thin-layer chromatography (TLC) 
on Kieselgel 60 plates as described previously (Morita et al., 2000a; Morita et al., 
2000b; Paul et al., 2004). Labeled lipid species were identified based on known 
migration patterns in this TLC system (Doering et al., 1993) or co-migration with 
the following markers: [3H]myristate for all free fatty acids, [1-14C]dimyristoyl 
phosphatidylcholine (American Radiolabeled Chemicals) for the various 
phospholipid species, and the bloodstream-specific VSG anchor precursors, 
Glycolipids A and C, which were generated using a cell-free 
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glycosylphosphatidylinositol anchor biosynthesis reaction (Morita et al., 2000a; 
Paul et al., 2004). To analyze the fatty acids by chain length, total lipid extracts 
were converted to fatty acid methyl esters (FAMEs), extracted in hexane, equal 
DPMs were loaded per lane (4,000-10,000), and analyzed by C18 reverse-phase 
TLC (Morita et al., 2000b; Paul et al., 2004). For chain length markers, FAMEs 
were prepared in parallel from [11,12-3H]laurate (C12), [9,10-3H]myristate (C14), 
[9,10-3H]palmitate (C16), and [9,10-3H]stearate (C18). Semi-quantitative analysis 
of TLCs was performed using densitometry (NIH Image J software) of 
appropriately exposed autoradiographic films with an unsaturated signal within 
the linear range of the film. To determine fatty acid elongation, each FAME spot 
was quantified and then calculated as follows: total C12 elongation = 100 x ([C14 
+ C16 + C18]/[C12 + C14 + C16 + C18]); total C14 elongation = 100 x ([C16 + 
C18]/[C14 + C16 + C18]). 
Mouse Infections 
Analysis of ACC RNAi in mice was performed essentially as described 
(Lecordier et al., 2005). 20 Female NIH Swiss mice (10-12 weeks) were divided 
into 2 groups of 10 and pre-treated via their drinking water for 2 days with either 
1 mg/ml doxycycline/ 5% sucrose (+ RNAi group) or 5% sucrose alone (no RNAi 
group). Doxycycline is a bioavailable tetracycline analog that will induce RNAi in 
vivo (Lecordier et al., 2005) and does not itself affect the course of infection 
(Rothberg et al., 2006; Abdulla et al., 2008). Mice were then infected by 
intraperitoneal injection with 1 x 105 bloodstream form ACC RNAi cells freshly 
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thawed from frozen stabilates. Mice were maintained on treated water for the 
duration of the experiment, with fresh changes every 2 days. Course of infection 
was monitored and time to death was recorded. Parasitemias were monitored 
periodically in a randomly selected sub-set of mice by tail stick and examination 
of blood smears. Mice were monitored daily for general appearance, behavior, 
and weight loss. If a mouse reached a humane endpoint (parasitemia ≥ 108, 
>20% weight loss, or obvious distress) the mouse was euthanized and time of 
death marked as the following day. Trypanosomes were purified from blood by 
DE52 anion exchange chromatography (Lonsdale-Eccles and Grab, 1987) and 
equal cell equivalents were assessed for ACC protein by SA-HRP blotting as 
described above. Kaplan-Meier analysis was performed using JMP software. 
Experiments were carried out in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) of Clemson University. 
ClustalW Alignment of ACCs 
Full-length sequence of the TREU 927 T. brucei ACC gene 
(Tb927.8.7100) and the Leishmania major ACC gene (LmjF31.2970) were 
downloaded from the TriTrypDB genome database (www.TriTrypDB.org (Aslett 
et al., 2009)). The Trypanosoma cruzi ACC gene was reconstructed from two 
unlinked DNA sequence fragments (TcChr31-S nt 149040-152627 (+2) and 
TcChr31-S nt 152824-155282 (+3)) downloaded from TriTrypDB. ACC gene 
sequences for Saccharomyces cerevisiae ACC (Accession # AAA20073) and 
human ACC1 (Isoform 1, Accession # NP_942131) were downloaded from 
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National Center for Biotechnology Information (NCBI). Alignments were 
performed using ClustalW (Larkin et al., 2007) followed by some manual 
adjustments. 
ACC-MYC Immunoprecipitation and ACC Assay 
Lysates from 2.5 x 108 cells were created by addition of 600 µl of 
hypotonic buffer and vigorous shearing through a 27.5 gauge needle. Lysates 
were then centrifuged for 10 min at 1000 x g to remove cellular debris. Following 
centrifugation, a 500 µl sample of cleared lysate was aspirated and added to 10 
µl of immobilized anti-C-myc  agarose beads (5 µg of anti-C-myc antibody in 2.5 
µL settled agarose beads) (Thermo Scientific) and incubated end-over-end at 
4°C for 1 h. The beads were then centrifuged, washed twice, and resuspended in 
150 µl of BC buffer. Two-fold serial dilutions were made in BC buffer and 
assayed for ACC enzymatic activity as described in Experimental Procedures. 
Total activity was normalized to the “no lysate” control. 
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FIGURES 
Figure 2.1: T. brucei Acetyl-CoA Carboxylase (TbACC) Gene Structure. A. 
Cartoon showing comparative enzyme architectures of T. brucei ACC (TbACC), 
Saccharomyces cerevisiae ACC1 (ScACC1), and human ACC1 (HsACC1). 
Entire protein sequence (black line) with Biotin carboxylase (BC) domains 
(hatched boxes), Biotin Carboxyl Carrier Protein (BCCP) Domains (black boxes), 
and Carboxyltransferase (CT) domains (white boxes) are drawn to scale. 
Conserved phosphorylation sites are indicated by capital Ps above the line. B. 
Alignment of the N-terminal sequences of TbACC, ScACC1, and HsACC1. The 
two conserved N-terminal serine phosphorylation sites in HsACC1 are indicated 
by shadowboxing. The first part of the conserved Biotin Carboxylase (BC) 
domain is in bold text and indicated by black bar underneath the text. 
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Figure 2.2: ClustalW alignment of ACC genes from T. brucei, S. cerevisiae 
ACC1, and human ACC1. Identical residues are shaded in black, conserved 
residues are shaded in gray. ATP-binding motif (ATP) and biotinylation site 
(biotin) are boxed. Asterisks mark residues important for binding and/or catalysis 
as indicated by the crystal structure and/or mutational analyses. 
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Figure 2.3: ClustalW alignment of ACC genes from three trypanosomatids: 
T. brucei, T. cruzi, and L. major. Identical residues are shaded in black, 
conserved residues are shaded in gray. ATP-binding motif (ATP) and 
biotinylation site (biotin) are boxed. Asterisks mark residues important for binding 
and/or catalysis as indicated by the crystal structure and/or mutational analyses. 
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Figure 2.4: ACC Transcribed in Both Bloodstream and Procyclic Forms. A. 
Total RNA (~1 x 107 cell equivalents) was probed for ACC by northern blotting 
with a 32P-labelled DNA probe. Loading control is ethidium bromide stained 
ribosomal RNAs (EtBr rRNAs). gDNA, genomic DNA. B. Total lysates (20 µg 
protein) were probed for ACC by blotting with SA-HRP, which recognizes the 
ACC biotin prosthetic group. Loading control is lower half of blot probed for 
tubulin. C. ACC activity was measured in lysates (100 µg of protein) of 
bloodstream forms (BF; gray bars) and procyclic forms (PF; white bars) by 
assaying the conversion of [14C]sodium bicarbonate into the acid-resistant 
[14C]malonyl-CoA product, which was dried onto filters and measured by 
scintillation counting. Lysate concentration was within linear range for the assay. 
Values were normalized to no lysate controls before averaging. Mean of 6 
experiments is shown. Error bars indicate the SEM (p >0.5 for difference 
between bloodstream and procyclic form activity, Student’s t-Test). 
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Figure 2.5: ACC Activity is evident in anti-C-myc immunoprecipitation from 
ACC-MYC cell lysate. Lysate from procyclic form ACC-myc cells (light gray 
bars) and control 29-13 cells (black bars) were subjected to immunoprecipitation 
with anti-c-myc coated latex beads. Washed beads containing bound proteins 
were serially-diluted and assayed for ACC activity by measuring the conversion 
of [14C]sodium bicarbonate to [14C]malonyl-CoA by scintillation counting of the 
acid-resistant product. Total activity of each sample was normalized to the “no 
lysate” control. 
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Figure 2.6: Sub-Cellular Fractionation Shows ACC to be Cytosolic. A. 
Scheme for sub-cellular fractionation by differential centrifugation of lysates 
prepared from procyclic form ACC-myc cells. B. Starting lysate (L) and sub-
cellular pellet (P) and supernatant (S) fractions were probed by western blotting 
for ACC-myc (c-myc), total ACC (SA-HRP), cytoplasmic HSP70 (cytoplasmic 
marker), glycosomes, and BiP (ER marker). The anti-glycosome antibody 
recognizes three glycosomal enzymes: pyruvate phosphate dikinase (PPDK) 
(~100 kD), aldolase (~41 kD), and glyceraldehyde phosphate dehydrogenase 
(GAPDH) (~39 kD). The identity of the ~50 kD band is not known. Example 
shown is representative of two independent fractionations. 
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Figure 2.7: Immunofluorescence microscopy shows ACC distribution is 
distinct from glycosomes. Procyclic form ACC-myc cells were fixed 
permeabilized, and ACC-myc (green) localized with mouse anti-c-myc primary 
antibody and Alexa-Fluor 488 conjugated goat anti-mouse secondary antibody 
(B, F). Glycosomes (red) were localized with rabbit anti-glycosome primary 
antibody and Alex-Fluor 594 conjugated goat-anti-rabbit secondary antibody (C, 
G). Merged views show the red and green channels (D, H). Cells were co-stained 
with DAPI (blue) to indicate nuclear and mitochondrial DNA (A, E). Cells were 
imaged at 100X. Scale bars = 10 µm. 
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Figure 2.8: Immunofluorescence Microscopy Shows ACC is Localized to 
Cytoplasmic Puncta. A–H. Procyclic form ACC-myc cells (A–D) and wild-type 
procyclic cells (E–H) were fixed, permeabilized, and ACC-myc localized by 
staining with mouse anti-c-myc primary antibody and Alexa-Fluor 488 conjugated 
goat anti-mouse secondary antibody (green). I–X. Procyclic form ACC-myc cells 
were co-localized for ACC-myc as above (green) along with rabbit antibodies for 
various sub-cellular markers: I–L, glycosome (anti-glycosomal); M–P, cytoplasm 
(anti-cytoplasmic HSP70); Q–T, ER (anti-BiP); and U–X, mitochondrion (anti-
lipoamide dehydrogenase (LipDH)). Secondary antibody was goat-anti-rabbit 
conjugated to Alex-Fluor 594 (red). Y–Z. Wild-type procyclic cells were stained 
with Nile red to show lipid droplets. All cells were co-stained with DAPI (blue) to 
indicate nuclear and mitochondrial DNA. Cells were imaged at 100X (A, B, E, F, 
I–Z) and 60X (C,D,G,H). Scale bars = 10 µm. 
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Figure 2.9: RNA interference of ACC in Bloodstream and Procyclic Forms. 
A. Total RNA (10-15 µg) was isolated from ACC RNAi cells after 2 days of RNAi 
induction (+ RNAi) or from uninduced controls (– RNAi) and probed for ACC by 
northern blotting with a 32P-labelled DNA probe corresponding to the ACC RNAi 
target sequence. ACC mRNA, the Tet-induced double-stranded RNA (dsRNA), 
and contaminating genomic DNA (gDNA) are indicated at the right. Loading 
control is ethidium bromide stained ribosomal RNAs (rRNAs). One of 4 
independent clones with similar results is shown. B. ACC RNAi cells were 
induced for 0–10 days. Total cell lysates (20 µg) from each time point were 
probed for ACC by SA-HRP blotting. Blot is over-exposed to show non-specific 
cross-reacting bands. A representative of 2 independent experiments is shown. 
C. ACC RNAi cells were induced for 4 days and hypotonic lysates from induced 
(+ RNAi) and uninduced control cells (no RNAi) were assayed for ACC activity by 
measuring the conversion of [14C]sodium bicarbonate to [14C]malonyl-CoA by 
scintillation counting of the acid-resistant product. Inset shows SA-HRP blotting 
of the same lysates to indicate extent of ACC RNAi. A representative of 2 
independent experiments is shown. D. ACC RNAi cells were induced and cell 
growth was monitored for 14 days (+ RNAi) in comparison to control uninduced 
cultures (no RNAi). Asterisk indicates when RNA was isolated for the northern 
blot. A representative of 4 independent experiments is shown. 
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Figure 2.10: ACC RNAi reduces ACC activity, but has no effect on growth in 
normal media. A. ACC RNAi cells were induced for 4 days and hypotonic 
lysates from induced (+ RNAi; closed symbols) and uninduced control cells (no 
RNAi; open symbols) were assayed for ACC activity by measuring the 
conversion of [14C]sodium bicarbonate to [14C]malonyl-CoA by scintillation 
counting of the acid-resistant product. Total activity was normalized to “no lysate” 
control. Linear regression of pooled data from all independent experiments is 
shown (n=2 for bloodstream (left panel); n=3 for procyclic (right panel)). B. Linear 
regression correlation coefficients of ACC activity data in panel A. ACC RNAi 
reduced ACC activity by 87 ± 1% and 90 ±1% in bloodstream (gray bars) and 
procyclic cells (open bars), respectively. Error bars indicate SEM (p <0.0005 for 
difference between No RNAi and +RNAi, Student’s t-Test). C. ACC RNAi cells 
were induced (+RNAi) or left uninduced (No RNAi), and cell growth monitored for 
up to 14 days. Doubling times for bloodstream (gray bars) and procyclic (open 
bars) trypanosomes were determined from 4 independent growth curves. Error 
bars indicate SEM (p >0.1 for difference between No RNAi and +RNAi, Student’s 
t-Test). 
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Figure 2.11: ACC RNAi Reduces Fatty Acid Elongation. A. ACC RNAi cells 
were induced for 7 days. Induced (+ RNAi) and uninduced (– RNAi) cells were 
then incubated with 50 µCi of [3H]laurate (C12) or [3H]myristate (C14) for 2 h. 
Total lipids were extracted in chloroform/methanol (final 
chloroform/methanol/water ratio of 10:10:3) and equal DPMS per lane were 
loaded and resolved on Kieselgel 60 plates with chloroform/methanol/water 
(10:10:3) as the mobile phase. Plates were sprayed with En3Hance, dried, and 
exposed to film. Cell type, RNAi conditions, and type of [3H]fatty acid label are 
indicated at the top. The origin (O) and lipid markers (M) (myristate (Myr), 
phosphatidylcholine (PtdC), and VSG GPI anchor precursors glycolipid C (C) and 
A (A)) are indicated at the right. Relative migration of neutral lipids (NL), free fatty 
acids (FFA), phospholipids (PL), and VSG GPI synthesis pathway products are 
indicated on left. Asterisk indicates putative phosphatidylethanolamine species. 
Lane numbers and marker lane (M) are indicated at the bottom. A representative 
of two independent experiments is shown. B. The fatty acids in the total lipid 
extracts in panel A were converted to FAMEs, extracted in hexane, and equal 
DPMs per lane were loaded and resolved by C18 reverse-phase high-
performance TLC using chloroform/methanol/water (5:15:3) as the mobile phase. 
Plates were sprayed with En3Hance, dried, and exposed to film. RNAi conditions 
and type of label are indicated at the top. The origin (O) and lipid markers for 
C12, C14, C16, and C18 FAMEs are indicated at the right. Lane numbers and 
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marker lane (M) are indicated at the bottom. A representative of two independent 
experiments is shown. 
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Figure 2.12: Growth of ACC RNAi Cells in Low Lipid Conditions. ACC RNAi 
cells were seeded into normal or low-lipid media, induced for ACC RNAi for 10 
days, and the cell densities of induced (+RNAi) and uninduced control (No RNAi) 
cultures were recorded every other day. A. Bloodstream form ACC RNAi cells in 
normal medium (NM), or two types of low-lipid media: medium made with 
delipidated FBS (DL) and medium made with only Serum Plus (SP). B. Procyclic 
form ACC RNAi in normal medium (NM) or low-lipid medium made with 
delipidated FBS (DL). C. Procyclic form ACC RNAi in DL medium or DL medium 
supplemented with 35 µM stearate (DL + C18). For all panels, average of three 
replicates is shown. Error bars show SEM, but are smaller than the data 
symbols. 
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Figure 2.13: Pre-adaptation in low lipid media does not alter effect of ACC 
RNAi on growth. A. ACC RNAi cells were seeded into normal or low-lipid media, 
grown for 10 days (pre-adaptation), then induced for ACC RNAi for an additional 
10 days. Cell densities of induced (+RNAi, closed symbols) and uninduced 
control (No RNAi; open symbols) cultures were recorded every other day during 
the RNAi induction. For each sample, the first medium listed is the pre-adaptation 
medium and the second medium listed is the induction medium (e.g. NM/NM 
means pre-adapted in NM and induced NM). A. Bloodstream form ACC RNAi 
cells in normal medium (NM), or two types of low-lipid media: medium made with 
delipidated FBS (DL) and medium made with only Serum Plus (SP). B. Procyclic 
form ACC RNAi in normal medium (NM) or low-lipid medium made with 
delipidated FBS (DL). Experiment was performed in duplicate. 
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Figure 2.14: ACC RNAi Cells Show Reduced Virulence in a Mouse Model of 
Infection. Kaplan-Meier survival analysis of mice infected with bloodstream form 
ACC RNAi trypanosomes. NIH Swiss mice (10 per group) were pre-dosed in their 
drinking water for 48 h with 1 mg/ml doxycycline in 5% sucrose water (+ RNAi) or 
5% sucrose water as a control (No RNAi). At 48 h, mice were infected by intra-
peritoneal injection of 1 x 105 ACC RNAi trypanosomes and monitored for time of 
death for 30 days. Mice were maintained on the doxycycline/sucrose or sucrose 
water for the duration. Significance was determined by Wilcoxon Test. 
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CHAPTER THREE 
INHIBITION OF Trypanosoma brucei ACETYL-COA CARBOXYLASE BY 
HALOXYFOP 
Patrick A. Vigueira and Kimberly S. Paul 
Department of Biological Sciences, Clemson University, Clemson, SC 
ABSTRACT 
Trypanosoma brucei, a eukaryotic pathogen that causes African sleeping 
sickness in humans and nagana in cattle, depends on the enzyme acetyl-CoA 
carboxylase (ACC) for full virulence in mice. ACC produces malonyl-CoA, the two 
carbon donor for fatty acid synthesis. We assessed the effect of haloxyfop, an 
aryloxyphenoxypropionate herbicide inhibitor of plastid ACCs in many plants as 
well as Toxoplasma gondii, on T. brucei ACC activity and growth in culture. 
Haloxyfop inhibited TbACC in cell lysate (EC50 67 µM), despite the presence of 
an amino acid motif typically associated with resistance. Haloxyfop also reduced 
growth of bloodstream and procyclic form parasites (EC50 of 0.8 mM and 1.2 
mM). However, the effect on growth was likely due to off-target effects because 
haloxyfop treatment had no effect on fatty acid elongation or incorporation into 
complex lipids in vivo.  
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INTRODUCTION 
Trypanosoma brucei is a protozoan parasite and the etiological agent of 
human African trypanosomiasis, also known as African sleeping sickness. The 
disease causes significant morbidity and mortality across its range in sub-
Saharan Africa. The World Health Organization estimates that 60 million people 
are at risk of contracting sleeping sickness (WHO, 2010). Livestock and working 
animals are also susceptible to infection, and the resulting disease, nagana, is 
estimated to cause 4.5 billion dollars in trypanosome-related agricultural losses 
each year (FAO, Food and Agricultural Organization of the United Nations, 
2007).  
The public health consequences and enormous economic burden caused 
by T. brucei highlight the desperate need for new chemotherapeutic treatments 
for these diseases. Currently, available drugs have substantial negative side 
effects, and parasite drug resistance is an ever-present concern (Burri, 2010). 
Vaccine development is not a viable option. This strategy is confounded by the 
parasite’s ability to change its glycoprotein surface coat through a process called 
antigenic variation (Horn et al., 2010). 
Previously, we reported that T. brucei acetyl-CoA carboxylase (TbACC) is 
required to efficiently establish and maintain an infection in a mouse model 
(Vigueira et al., 2011). Knockdown of TbACC by RNA interference (RNAi) nearly 
doubled the mean time until death, suggesting TbACC is a suitable candidate for 
investigation as a drug target. In T. brucei, TbACC exists as a single 
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cytoplasmically-disposed isoform. TbACC is a large multidomain enzyme, 
consisting of biotin carboxylase, biotin-carboxyl carrier protein (BCCP), and 
carboxyl-transferase (CT) domains. ACC catalyzes the first committed step in 
fatty acid synthesis (FAS): the ATP-dependent carboxylation of acetyl-CoA to 
make malonyl-CoA, the two-carbon donor for FAS (Vigueira et al., 2011). In lieu 
of a conventional fatty acid synthase, the parasite utilizes a series of microsomal 
elongases (ELO) for the bulk of FAS (Lee et al., 2006). See (Lee et al., 2007) for 
review of T. brucei FAS. 
ACC has long been recognized as a useful target for chemical intervention 
in crop management. The aryloxyphenoxypropionates (FOPs) and the 
cyclohexanediones (DIMs) are ACC inhibitors commonly used to control grass 
weeds affecting a number of agricultural crops (e.g. leaf vegetables, onion, 
strawberry). The FOPs and DIMs target the plastid ACCs of grasses by binding 
the CT domain and causing conformational changes that prevent transfer of the 
carboxyl group from the BCCP domain to the acetyl-CoA substrate (Delye et al., 
2003; Zhang et al., 2004; Xiang et al., 2009).  
Research into weed FOP- and DIM-resistance mechanisms has identified 
two amino acid residues in ACC that appear important in determining resistance 
status. In the yeast, Saccharomyces cerevisiae, these residues are L1705 and 
V1967, and according to the crystal structure, these residues lie in the haloxyfop 
binding pocket of the CT domain (Zhang et al., 2004). In rye grass, Lolium 
rigidum, a single change from the native I at either of these important residues is 
 110
sufficient to confer resistance to FOPs, specifically haloxyfop (Zagnitko et al., 
2001; Delye et al., 2003). However, a growing body of evidence suggests that 
these residues are likely just two of multiple potential residues in the highly 
conserved CT domain capable of influencing FOP sensitivity (Zhang et al., 2004; 
Zhang et al., 2006a; Zhang et al., 2006b; Liu et al., 2007). 
ACC and lipid metabolism have also been identified as potential drug 
targets for treating parasitic protozoan infections (Surolia et al., 2001; Roberts et 
al., 2003; Paul et al., 2004; Singh et al., 2009). In particular, haloxyfop has been 
demonstrated to inhibit the apicoplast-localized ACC of the apicomplexan 
parasite Toxoplasma gondii (Zuther et al., 1999). Here, we report the sensitivity 
of a second protozoan ACC to haloxyfop. Despite possessing the amino acid 
sequence motif typically associated with haloxyfop resistance, TbACC is inhibited 
by haloxyfop. We demonstrate that haloxyfop kills insect midgut stage, procyclic 
form (PF) and mammalian bloodstream form (BF) parasites in vitro. However, in 
vivo lipid metabolism is not detectably influenced upon treatment, suggesting that 
the toxicity of haloxyfop to T. brucei cannot be entirely attributed to TbACC 
inhibition.  
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RESULTS 
Effect of FOPs and sethoxydim on TbACC activity 
 We tested 4 compounds from the FOP family and a single representative 
from the DIM family of herbicides for their effect on TbACC enzymatic activity in 
PF lysate. TbACC activity is assayed in desalted cell lysate by measuring the 
incorporation of the [14C]CO2 from [14C]NaHCO3 into the acid-resistant 
[14C]malonyl-CoA product (Vigueira et al., 2011). Haloxyfop was the most potent 
inhibitor of the assay with an EC50 of 67 µM, and EC90 of 400 µM (Fig. 3.1E). The 
other tested FOPs (clodinafop, fluazifop, quizalifop) and the DIM compound 
(sethoxydim) had either no inhibitory activity or had EC50 values >400 µM (Fig. 
3.1A-D). As haloxyfop showed promising activity, we used this compound in our 
subsequent studies.  
TbACC contains residues that confer resistance in other ACCs 
 Previous work on FOPS has revealed that resistance can be traced to 
two key amino acid residues in the haloxyfop binding pocket of the ACC CT 
domain, L1705 and V1967 in Saccharomyces cerevisiae (Zhang et al., 2004). In 
ACCs that have been experimentally determined to be resistant to inhibition by 
haloxyfop, the proteins possess the L/V motif at equivalent positions (Fig. 3.2). 
However, in sensitive ACCs, there are typically deviations from this pattern at 
either or both positions: L-1705-I or V-1967-I variants. TbACC has an L/V pair 
(L1650 and V1912) identical to the yeast L/V pair and would therefore be 
predicted to be resistant to haloxyfop.     
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Effect of haloxyfop on growth in culture 
 We have previously demonstrated that RNAi of ACC causes little 
reduction in parasite growth rate when cells are cultured in normal media 
(Vigueira et al., 2011). Therefore, we sought to determine the maximum 
concentration of haloxyfop that could be tolerated by the parasites without having 
a major impact on growth rate. For growth of PF cells, haloxyfop concentrations 
up to 100 µM had no significant effect on doubling time, though 250 µM 
haloxyfop caused a slight, statistically significant increase (Fig. 3.3B). For BF 
cells, growth remained unchanged in the presence of up to 250 µM haloxyfop 
(Fig. 3.3E). The overall effect on growth rate over ten days was minimal in both 
PF and BF parasites (Fig. 3.3A, D), suggesting that potentially lethal, off-target 
effects are kept to a minimum at haloxyfop concentrations ≤250 µM. At higher 
haloxyfop concentrations (250 µM to 2 mM), we observed a statistically 
significant reduction in cell growth over 48 h (Fig. 3.3C, F) with an EC50 of 1.2 
mM for PF parasites and an EC50 of 0.8 mM for BF parasites.  
We detected a slight effect of the DMSO solvent on growth, with a 9% and 
17% reduction in PF and BF parasites, respectively. The effect of 1% v/v DMSO 
on BF parasite viability has been quantified previously and is consistent with our 
observations (Sharlow et al., 2010).  
Effect of haloxyfop on fatty acid elongation 
 To determine whether haloxyfop treatment targets TbACC in intact cells, 
we assessed FA elongation in vivo as T. brucei will readily take up, elongate and 
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incorporate exogenous fatty acids into more complex lipids. We used haloxyfop 
concentrations that did not exhibit a major growth defect in PF parasites, as our 
previous work showed that ACC RNAi inhibited in vivo fatty acid elongation while 
showing no growth defect in normal media (Vigueira et al., 2011). After a 4 day 
treatment with 10–250 µM haloxyfop, we incubated PF cells with [3H]laurate 
(C12:0) and assessed its elongation by the ELO pathway. A chain length 
analysis of FAMEs by reverse-phase TLC demonstrated no reduction in the 
ability of the parasite to elongate [3H]laurate (C12:0) to longer fatty acids (C14:0, 
C16:0, C18:0) upon haloxyfop treatment (Fig. 3.4B). Additionally, normal phase 
TLC of bulk lipids revealed no gross differences between haloxyfop-treated and 
untreated parasites in the level of incorporation of [3H]laurate into phospholipids, 
free fatty acids, or neutral lipids (Fig. 3.4A).  
Effect of haloxyfop on ACC protein levels 
 We next examined the possibility that the parasite compensated for 
haloxyfop inhibition by increasing ACC protein expression. ACC protein can be 
detected by western blotting with SA-HRP, which recognizes the biotin prosthetic 
group of ACC (Nikolau et al., 1985; Haneji et al., 1989; Vigueira et al., 2011). 
After 4 days of haloxyfop treatment (10-250 µM), we observed no statistically 
significant changes (p >0.01) in ACC protein levels when normalized to β-tubulin 
protein levels (Fig. 3.5). 
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DISCUSSION 
Of the FOP and DIM compounds we tested, haloxyfop had the greatest 
inhibitory effect on TbACC activity in lysate (EC50 of 67 µM) (Fig. 3.1). The EC50 
for haloxyfop on TbACC was determined with lysate rather than with purified 
protein, thus it is difficult to directly compare to other IC50s reported for purified 
ACCs. Direct comparison of TbACC to other ACCs is also problematic because 
of the lab-to-lab variation in experimental procedure reported in the literature. 
With these limitations in mind, the sensitivity of TbACC in cell lysate is most 
similar to the moderate sensitivity described for that of the protozoan parasite T. 
gondii (IC50 20 µM) (Zuther et al., 1999) and the Norway rat, R. norvegicus (IC50 
120 µM), (Kemal et al., 1992). Our data also suggests TbACC is less sensitive to 
haloxyfop than the plastid ACCs of ryegrass, corn, and blackgrass (IC50 1-3 µM) 
(Secor et al., 1988; De Prado et al., 2000; Delye et al., 2003) and more sensitive 
than the ACC CT domain of the yeast, S. cerevisiae (IC50 ~1.1 mM) (Zhang et al., 
2004).  
The moderate sensitivity of TbACC to haloxyfop is somewhat surprising 
based on the presence of the L/V variant previously determined to confer 
resistance to this compound. Amino acid changes at these two positions cause 
sensitive plant ACCs to become resistant to FOPS and DIMS (Zagnitko et al., 
2001; Brown et al., 2002; Christoffers et al., 2002; Delye et al., 2003; White et al., 
2005; Zhang et al., 2006a). With the exception of the Norway rat, organisms 
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containing native ACCs with L/V variants are comparatively resistant to haloxyfop 
(Fig. 3.2). 
The finding that TbACC possess the L/V variant and exhibits moderate 
sensitivity supports previous work indicating that although these residues appear 
important for conferring resistance, they alone are not necessarily predictive of 
sensitivity. Other residues in and around the haloxyfop binding pocket are likely 
to affect sensitivity and may moderate the effects of any single residue (Zhang et 
al., 2004; Zhang et al., 2006a; Liu et al., 2007). Evidently, the sensitivity of ACCs 
to haloxyfop lies on a continuum, making it difficult to classify the ACC of any one 
organism as either “sensitive” or “resistant”.  
Treatment of PF and BF parasites with haloxyfop concentrations up to 250 
µM had a minimal effect on parasite growth and doubling time (Fig. 3.3A-B, D-E). 
However, this effect was minor compared to the dramatic effect of higher 
haloxyfop concentrations on PF and BF parasite growth over 48 h (Fig. 3.3C, F). 
BF parasites were slightly more sensitive to haloxyfop treatment than PF 
parasites. However, both PF and BF T. brucei were remarkably less sensitive to 
haloxyfop than T. gondii (EC50  ~100 µM) (Zuther et al., 1999). We have 
previously demonstrated through RNAi experiments that TbACC is largely 
expendable in BF parasites in vitro and is only required when PF parasites are 
cultured in low-lipid media (Vigueira et al., 2011). Thus, we contend that inhibition 
of TbACC by haloxyfop should have little to no consequence on the growth rate 
of the parasite in vitro. Consequently, the reduction in growth we observed with 
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haloxyfop concentrations >250 µM can be attributed to off-target effects rather 
than inhibition of TbACC.  
Our previous work demonstrated that reduction of TbACC by RNAi causes 
a robust reduction in elongation of fatty acids in PF parasites (Vigueira et al., 
2011). Given that haloxyfop treatment inhibited TbACC activity in lysate, the 
inability of haloxyfop to affect FAS in vivo was unexpected (Fig. 3.4). Assessing 
the effect of haloxyfop concentrations >250 µM on fatty elongation in vivo was 
not feasible, because any observed effects could not be separated from those 
resulting from the profound effect of the compound on parasite growth due to 
likely off-target effects (Fig. 3.3C, F).  
One possible explanation for this disparity between haloxyfop’s effect in 
lysate and intact cells could be a compensatory increase in TbACC protein 
expression, a possibility that we ruled out (Fig. 3.5). It is also possible that 
incomplete inhibition of TbACC allowed available malonyl-CoA pools to remain 
high enough that ELO activity appeared unaffected. Alternatively, the apparent 
insensitivity of TbACC to haloxyfop in intact cells may be due to the fact that the 
compound does not efficiently enter the cell or is partitioned into a cellular 
compartment not accessible to TbACC. Haloxyfop’s effect on growth at higher 
concentrations (Fig. 3.3C, F) does not negate poor membrane permeability as a 
possible explanation because haloxyfop could be acting at the cellular surface to 
cause a reduction in growth. Depolarization of the cellular membrane has been 
described in plants and is considered a secondary mechanism for the 
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graminicide activity of FOPs (Hausler et al., 1991; Shimabukuro et al., 1992; 
Ditomaso,1994; Holtum et al., 1994; Wright,1994).   
Another possible explanation is that haloxyfop is modified in intact T. 
brucei, rendering it unable to bind and inhibit TbACC. Because the haloxyfop 
binding pocket lies in a tight space on the face of the ACC protein dimer, any 
small modification of the compound could reduce the ability of haloxyfop to bind 
and inhibit enzymatic activity (Zhang et al., 2003). Stereochemical inversion of 
haloxyfop has been observed previously in rats (Bartels et al., 1989), however 
the inhibitory activity of the resulting enantiomer has not been determined.  
In summary, we have demonstrated that haloxyfop inhibits TbACC in vitro, 
but has no detectable effect on in vivo lipid metabolism, suggesting that the 
toxicity of haloxyfop to T. brucei cannot be entirely attributed to TbACC inhibition. 
To our knowledge, this is the first report of potential off-target effects of this class 
of inhibitors in protozoan parasites. Furthermore, this study highlights the need 
for careful characterization of the mechanisms of action of small molecule 
inhibitors in lysates as well as in intact cells. 
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MATERIALS AND METHODS 
 Reagents 
 All chemicals and reagents were purchased from Thermo Fisher Scientific 
and Sigma, except: Serum Plus (JRH Biosciences) and streptavidin conjugated 
horseradish peroxidase (SA-HRP) (Pierce). Minimum Essential Medium, Iscove’s 
Modified Dulbecco’s Medium, and goat anti-mouse-HRP IgG antibody were from 
Invitrogen. [14C]NaHCO3 and 3H-labeled fatty acids were from American 
Radiolabeled Chemicals. Silica Gel 60 and C18 reverse phase thin layer 
chromatography (TLC) plates were from Analtech. The mouse anti-tubulin 
antibody (clone B-5-1-2) was from Sigma. Clodinafop (CAS-No: 105512-06-9), 
haloxyfop (CAS-No: 74051-80-2), quizalifop (CAS-No: 94051-08-8) and 
sethoxydim (CAS-No: 74051-80-2) were from Sigma. Fluazifop (CAS-No: 69335-
91-7) was from Wako. 
Trypanosome strains and media 
  Wild-type (WT) strain 427 PF and BF T. brucei were provided by Dr. Paul 
Englund (Johns Hopkins School of Medicine). BF parasites were grown in HMI-9 
medium (Hirumi et al., 1989) containing 10% heat-inactivated FBS/10% Serum 
Plus. PF parasites were grown in SDM-79 medium (Brun et al., 1979) containing 
10% heat inactivated FBS.  
ACC enzyme activity 
 To assay ACC activity, we modified a biotin carboxylase assay described 
previously (Wurtele et al., 1990; Vigueira et al., 2011). Inhibitors were prepared in 
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filter-sterilized dimethyl sulfoxide (DMSO) and used as 100X stocks. Lysates 
were incubated with inhibitors for 30 min on ice prior to the addition of reaction 
components. The final reaction volume of 100 µl contained 5 mM ATP, 1 mM 
acetyl-CoA, 1% v/v DMSO and 5 mM [14C]NaHCO3 (14.9 mCi/mmol), and was 
incubated for 30 min at 30°C with constant mixing at 500 RPM. A 50 µl sample of 
acid-precipitated [14C]malonyl-CoA product was collected on Whatman #1 filters, 
air-dried, and quantified by scintillation counting.  
Growth experiments 
 For growth curves, WT cells were diluted into fresh media containing 
inhibitors or DMSO solvent control and cell density was monitored every 48 h for 
up to 10 days using a FACScan flow cytometer (Becton Dickinson). Inhibitors 
were prepared in filter-sterilized DMSO and used as 100X stocks, resulting in 
final DMSO concentration of 1% v/v. Following each cell count, cultures were 
diluted to maintain logarithmic phase growth, and inhibitors or DMSO was added 
to maintain experimental concentrations.  
Metabolic labeling and lipid analysis 
 Metabolic labeling was performed essentially as described (Paul et al., 
2004; Vigueira et al., 2011). Briefly, after 4 days of haloxyfop treatment, ~1 x 108 
PF cells were labeled with 25 µCi of [11,12-3H]laurate (C12:0; 60 mCi/mmol) for 
2 h in a 28°C CO2 incubator. Total lipids were extracted in 
chloroform/methanol/water (10:10:3 v/v/v) and equal CPMs/lane were analyzed 
by normal phase TLC using chloroform/methanol/water (10:10:3 v/v/v) as the 
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mobile phase. Labeled lipid species were identified based on known migration 
patterns in this TLC system (Doering et al., 1993). To analyze the fatty acids by 
chain length, total lipid extracts were converted to fatty acid methyl esters 
(FAMEs), extracted in hexane, and equal CPMs/lane were analyzed by C18 
reverse-phase TLC using chloroform/methanol/water (5:15:3 v/v/v) as the mobile 
phase. TLCs were sprayed with En3Hance (Perkin-Elmer) and exposed to x-ray 
film at -80°C. For chain length markers, FAMEs were prepared in parallel from 30 
µCi of [3H]fatty acids: [11,12-3H]laurate (C12; 60 mCi/mmol), [9,10-3H]myristate 
(C14; 60 mCi/mmol), [9,10-3H(N)]palmitate (C16; 60 mCi/mmol), and [9,10-
3H]stearate (C18; 60 mCi/mmol). 
Streptavidin blotting 
Streptavidin blotting can detect the biotin prosthetic group on ACC and 
was performed essentially as described (Vigueira et al., 2011). Briefly, PF 
parasites were treated for 4 days with haloxyfop. 20 µg of whole cell lysate were 
fractionated on 8% SDS-PAGE gels and transferred to nitrocellulose. The blot 
was cut, and the top half was probed for ACC with SA-HRP (1:400 in 0.2% dry 
milk, 1X Tris-buffered saline (TBS), 0.05% Tween-20). The bottom was probed 
with a mouse anti-tubulin (clone B-5-1-2), diluted 1:50,000 in Wash Buffer (5% 
dry milk, 1X TBS, 0.05% Tween-20) followed by HRP-conjugated goat anti-
mouse IgG secondary antibody diluted 1:10,000 in Wash Buffer. Semi-
quantitative analysis of blots was performed using densitometry (NIH Image J 
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software) of appropriately exposed films (unsaturated signal within the linear 
range of the film). 
Statistics 
 One-tailed Student’s t-test analyses between control and treatments were 
performed using Microsoft Excel. We judged statistical significance to be p < 
0.01. Error bars represent standard deviation from the mean.  
Genetic sequence acquisition  
 ACC protein sequences were acquired from the genetic sequence 
database at the National Center for Biotechnical Information. The accession 
numbers for each sequence are listed: Trypanosoma brucei (GenBank ID: 
XM_842447), Saccharomyces cerevisiae (GenBank ID: NM_001183193), Homo 
sapiens ACC1 (GenBank ID: U19822), Homo sapiens ACC2 (GenBank ID: 
U89344), Rattus norvegicus (GenBank ID: J03808), Toxoplasma gondii 
(GenBank ID: AF157612), Lolium rigidum (GenBank ID: AY995232), Zea mays 
(GenBank ID: U19183), and Alopecurus myosuroides (GenBank ID: AJ310767). 
 122
ACKNOWLEDGEMENTS 
 This work was supported in part by the National Institutes of Health 
1R15AI081207 (K.P.) and Clemson University Funds (K.P.). We thank members 
of the Clemson University Parasite Club for their helpful suggestions. We also 
thank Marianne Ligon, Ben Martin, and Ciara McKnight for experimental 
assistance and Jim Morris for critical reading of the manuscript.  
 123
FIGURES 
Figure 3.1: Effect of FOP and DIM herbicides on TbACC activity in PF 
lysate. ACC activity in PF cell lysates was measured after a 30 min incubation 
with 20-400 µM clodinafop (A), fluazifop (B), quizalifop (C), sethoxydim (D), or 
haloxyfop (E). Values are expressed as a percentage of the DMSO control. 
DMSO concentrations were maintained at 1% v/v for all conditions. The mean of 
3 experiments is shown. Error bars indicate the SD. The * indicates p < 0.01 for 
the difference between DMSO control and herbicide-treated conditions, Student’s 
t-test. 
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Figure 3.2: Alignment of multidomain ACC amino acid sequences 
surrounding the resistance-conferring residues in the CT domain. The 
organism and ACC protein resistance status are indicated in the far left column 
(sensitive (S), moderately sensitive (MS), resistant (R)). The resistance-
conferring residues, equivalent to S. cerevisiae L1705 and V1967, are 
highlighted and the highlighted numbers represent the equivalent amino acid 
positions in each sequence. Dashes indicate residues identical to those in T. 
brucei.  Accession numbers are provided in the far right column. The L. rigidum 
sequence is a partial cDNA sequence, thus the highlighted numbers refer to the 
amino acid positions in the partial gene product.  
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Figure 3.3: Effect of haloxyfop on in vitro growth of T. brucei. A,B,D,E. WT 
PF (A,B) and BF (D,E) cells were diluted into media containing 5–250 µM 
haloxyfop or DMSO control, and the cell densities of the cultures were recorded 
every other day for 8 days. Cumulative culture density is shown in A and D, and 
culture doubling times are shown in B and E. C,F. WT PF (C) and BF cells (F) 
were diluted into media containing 250 µM–2 mM haloxyfop or DMSO control, 
and the cell densities of the culture were determined after 48 h. Values are 
expressed as a percentage of DMSO control. For all panels, the mean of three 
replicates is shown. Error bars show SD. The * indicates p < 0.01 for the 
difference between DMSO and haloxyfop-treated conditions, Student’s t-test. 
 127
 
 128
Figure 3.4: Fatty acid incorporation and elongation in the presence of 
haloxyfop. WT PF cells were grown for 4 days in the presence of haloxyfop or 
DMSO. Cells were then incubated with 25 µCi of [3H]laurate (C12) for 2 h. A. 
Total lipids were extracted and equal CPMs per lane were resolved by TLC. The 
origin (O) and relative migration of neutral lipids (NL), free fatty acids (FFA), and 
phospholipids (PL) are indicated on the right. Treatment conditions are indicated 
at the top. B. Fatty acid chain length analysis of FAMEs prepared from the total 
lipid extracts in (A). Equal CPMs per lane were resolved by C18 reverse-phase 
high-performance TLC. The origin (O) and markers for C12, C14, C16 and C18 
FAMEs are indicated at the right. Treatment conditions are indicated at the top. A 
representative of two independent experiments is shown. 
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Figure 3.5: Effect of haloxyfop treatment on ACC protein levels. WT PF cells 
were grown for 4 days in the presence of 25–250 µM haloxyfop or DMSO. A. 
Total hypotonic lysates (20 µg protein) were probed for ACC by SA-HRP blotting, 
which recognizes the ACC biotin prosthetic group. The lower half of the blot was 
probed for tubulin as a loading control. Treatment conditions are indicated at the 
top. One representative of three independent blots is shown. B. Densitometric 
quantitation of ACC protein levels normalized to the α-tubulin loading control. 
Values are expressed as a percentage of the DMSO control. The mean of 3 
independent replicates is shown. Error bars indicate the SD. No significant 
difference was observed between DMSO and haloxyfop-treated conditions (p > 
0.01, Student’s t-test).  
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CHAPTER 4 
EFFECTS OF THE GREEN TEA CATECHIN EGCG ON Trypanosoma brucei 
Patrick A. Vigueira, Ben A. Martin and Kimberly S. Paul 
Department of Biological Sciences, Clemson University, Clemson, SC  
ABSTRACT 
Trypanosoma brucei, a eukaryotic pathogen that causes African sleeping 
sickness in humans and nagana in cattle, depends on the enzyme acetyl-CoA 
carboxylase (ACC) for full virulence in mice. ACC catalyzes the reaction that 
produces malonyl-CoA, the two carbon donor for fatty acid synthesis. We 
assessed the effect of the green tea catechin (−)-epigallocatechin-3-gallate 
(EGCG) on T. brucei ACC activity and growth in culture. EGCG inhibited TbACC 
in cell lysate (EC50 55 µM). However, inhibition of TbACC by EGCG was 
dependent upon the presence of phosphatase inhibitors in the cell lysate. EGCG 
also reduced growth of bloodstream (BF) and procyclic form parasites at 
supraphysiological concentrations (EC50 of 33 µM and 27 µM), but BF growth 
was unaffected at physiologically relevant concentrations (<0.1 µM). Additionally, 
EGCG treatment did not affect T. brucei virulence in a mouse model.  
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RESULTS AND DISCUSSION 
 
The protozoan parasite Trypanosoma brucei is the causative agent of 
African sleeping sickness, a fatal human disease that ranges across sub-
Saharan Africa. In addition to causing substantial morbidity and mortality in 
humans, T. brucei is responsible for causing nagana, a livestock disease that 
results in wasting and death. Nagana imposes a tremendous economic burden 
on the region, causing 4.5 billion dollars in economic losses each year (FAO, 
Food and Agricultural Organization of the United Nations,2007). Vaccine 
development is confounded by the parasite’s ability to switch its surface coat 
through antigenic variation (Horn et al., 2010). Thus, chemotherapeutics are 
relied upon to battle to the disease, yet currently approved drugs cause 
undesirable side effects and can be too expensive for citizens of economically 
depressed regions (Castillo et al., 2010). To meet this urgent need, investigations 
of existing compounds are an important avenue to identify potential new drugs 
that are effective, safe, and economical. 
Green tea is among the most widely consumed beverages worldwide and 
is often touted for its wealth of medicinal effects (Moon et al., 2007a; Khan et al., 
2008; Thielecke et al., 2009; Ahmed,2010). The best studied active component 
of green tea is the catechin (−)-epigallocatechin-3-gallate (EGCG). While EGCG 
likely impacts a number of cellular pathways, it has been demonstrated to inhibit 
fatty acid synthesis (FAS) (Wang et al., 2001; Brusselmans et al., 2003; Huang et 
al., 2009), through its effect on the regulation of acetyl-CoA carboxylase (ACC) 
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(Huang et al., 2009). ACC catalyzes the first committed step in FAS, the ATP-
dependent carboxylation of acetyl-CoA, which provides the two-carbon donor, 
malonyl-CoA, for FAS (Lee et al., 2008). ACC is negatively regulated by 
phosphorylation by AMP-activated protein kinase (AMPK), a key regulator of 
cellular energy metabolism (Barber et al., 2005; Brownsey et al., 2006). EGCG 
treatment leads to increased phosphorylation of human ACC, resulting in its 
inhibition (Moon et al., 2007b; Huang et al., 2009).  
In T. brucei, both the cytoplasmic and mitochondrial FAS pathways are 
important for parasite growth in culture and virulence in mouse models (Lee et 
al., 2006; Stephens et al., 2007; Vigueira et al., 2011). In addition, we have 
demonstrated recently that RNA interference (RNAi)-mediated gene knockdown 
of ACC in T. brucei reduced fatty acid elongation activity in intact cells and nearly 
doubled the mean time until death in a mouse model of infection (Vigueira et al., 
2011). Taken together, these results suggest that fatty acid synthesis has the 
potential to be an effective drug target in T. brucei.  
Here, we investigated whether EGCG could be used to target ACC and 
fatty acid synthesis in T. brucei. First, we tested EGCG for its ability to inhibit 
TbACC enzymatic activity in insect midgut stage, procyclic form (PF) lysate. 
TbACC activity is assayed in desalted cell lysate by measuring the incorporation 
of the [14C]CO2 from [14C]NaHCO3 into the acid resistant [14C]malonyl-CoA 
product, which is then quantified by scintillation counting (Vigueira et al., 2011). 
To preserve any changes in phosphorylation caused by EGCG, we added HALT, 
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a broad spectrum phosphatase inhibitor, to the cell lysate. In the presence of 
HALT, EGCG inhibited TbACC enzymatic activity with an EC50 of 55 µM (Fig. 
4.1). However, in the absence of HALT we observed no inhibition of TbACC by 
EGCG. These observations are consistent with the previously reported mode of 
action of EGCG, inhibition of ACC by increasing its phosphorylation (Moon et al., 
2007b; Huang et al., 2009). We contend that HALT, by inhibiting the parasite’s 
native phosphatases, preserved an EGCG-driven increase in ACC 
phosphorylation, resulting in decreased TbACC activity. We have made multiple 
attempts to quantify EGCG-induced TbACC phosphorylation, but to date we have 
been unsuccessful.  
We next examined the effect of EGCG on T. brucei growth in culture. In 
humans, the maximum reported EGCG plasma concentration achievable through 
oral consumption of concentrated green tea catechins ranges from 0.3–1 µM 
(Yang et al., 1998; Umegaki et al., 2001; Sugisawa et al., 2002; Unno et al., 
2005). A 6-day treatment of mammalian bloodstream form (BF) parasites at 
these physiological EGCG concentrations (0.1–1 µM) caused no change in BF 
parasite growth or doubling time (Fig. 4.2A,B). At supraphysiological EGCG 
concentrations, we observed a statically significant reduction in cell growth over 
48 h (Fig 4.2C,D), with an EC50 of 33 µM and 27 µM for BF and PF parasites, 
respectively. These values are consistent with the trypanocidal activity of EGCG 
previously reported for T. brucei rhodesiense (IC50 20.3 µM) (Tasdemir et al., 
2006). Based on our previous data showing that TbACC is largely expendable in 
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BF parasites in vitro and is only required when PF parasites are cultured in low-
lipid media (Vigueira et al., 2011),  we contend that inhibition of TbACC by EGCG 
should have little consequence on T. brucei growth in culture. Thus, the reduction 
in growth observed with EGCG concentrations >5 µM could be attributed to off-
target effects, rather than inhibition of TbACC.  
Finally, we examined the effect of EGCG treatment on the course of T. 
brucei infection in mice. Although the EC50 values for EGCG for growth in culture 
are greater than the maximum reported plasma concentrations in orally-dosed 
humans, there were two reasons to justify testing EGCG in a mouse model of 
infection. First, T. brucei exhibited condition-specific essentiality in the case of 
both TbACC and enoyl-CoA reductase (EnCR); PF ACC and EnCR RNAi cell 
lines exhibited slowed growth only when exogenous lipids were limited (Lee et 
al., 2006; Vigueira et al., 2011). In addition, TbACC RNAi and TbEnCR 
conditional knockout mutants had attenuated virulence in mice (Vigueira et al., 
2011 and Soo Hee Lee, personal communication). Second, previous studies of 
EGCG in mice yielded promising results for treatment of trypanosomiasis. 
Trypanosoma cruzi mortality in mice and parasite growth in culture was reduced 
with EGCG treatment (Paveto et al., 2004; Guida et al., 2007). In addition, 
inflammation caused by T. brucei infection was reduced with oral green tea 
supplementation in a mouse model (Karori et al., 2008). Taken together, these 
observations suggest that the parasite’s sensitivity to EGCG could be higher in 
vivo. 
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To test the ability of EGCG to clear a T. brucei infection in mice, we 
administered daily IP injections of 4.13 mg/kg EGCG in sterile H2O two days prior 
to infection and over the course of the trial. This EGCG concentration had been 
previously demonstrated to not cause mouse liver damage, (Guida et al., 2007). 
After 2 days of EGCG pre-treatment, Swiss mice were infected with 1x105 BF 
wild-type 427 parasites as previously described (Bacchi et al., 2009), and time to 
death (or humane end-point) was determined. In this model, EGCG treatment 
had no effect on infection duration or mouse mortality. Mean time until death was 
~3.5 days for both treatment and control groups (data not shown). Thus, although 
EGCG has trypanocidal activity at supraphysiological concentrations, the 
compound did not attenuate virulence in an acute infection mouse model. EGCG 
concentrations may not have been sufficiently high in the mouse bloodstream to 
affect the parasite. Alternatively, it is possible that the course of infection was too 
rapid to allow EGCG to exert its effects. If so, then a chronic infection model 
might be better suited to examine the efficacy of EGCG as a possible anti-
trypanosomiasis therapy. 
In summary, we found that TbACC is inhibited by EGCG in vitro, and this 
inhibition was dependent upon the presence of phosphatase inhibitors in the cell 
lysate. This suggests that EGCG could be a useful tool for studying the effects of 
phosphorylation on TbACC activity. We also demonstrated that EGCG kills both 
PF and BF parasites in culture. However, EGCG treatment did not affect T. 
brucei virulence in one mouse model of acute infection. 
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FIGURES 
Fig. 4.1: Inhibition of TbACC Activity by EGCG. ACC activity in PF cell lysates 
was measured in the presence of 5-100 µM EGCG (Sigma) in the absence (Grey 
bars) or presence (Black bars) of HALT phosphatase inhibitor cocktail (Thermo-
Pierce). EGCG was prepared in filter-sterilized dimethyl sulfoxide (DMSO) and 
used as a 100X stock. HALT was added as a 100X stock per the manufacturer’s 
instructions. The final reaction volume of 100 µL contained 5 mM ATP, 1 mM 
acetyl-CoA, 1% v/v DMSO and 5 mM [14C]NaHCO3 (14.9 mCi/mmol) and was 
incubated for 30 min at 30°C, mixing at 500 RPM. 6N HCl (50 µL) was added to 
terminate the reaction, and 50 µL of the acid-precipitated [14C]malonyl-CoA 
product was collected on Whatman #1 filters, air-dried, and quantified by 
scintillation counting. Values are expressed as a percentage of the DMSO 
control. DMSO concentrations were maintained at 1% v/v for all conditions. The 
mean of 3 experiments is shown. Error bars indicate the SD. The * indicates p 
<0.01 for the difference between DMSO control and EGCG-treated conditions 
(Student’s t-test). 
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Fig. 4.2: Effect of EGCG on in vitro growth of T. brucei. A and B. WT BF cells 
were diluted into HMI-9 media (Hirumi et al., 1989) containing 0.1-1 µM EGCG or 
DMSO as the solvent control, and the culture cell densities were monitored for 6 
days. Following each cell count, cultures were diluted to maintain logarithmic 
phase growth, and EGCG/DMSO was added to maintain experimental 
concentrations. Cumulative culture densities are shown in A, and culture 
doubling times are shown in B. Please note in A, all points overlap and error bars 
are too small to be visible. C and D WT BF (C) and PF cells (D) were diluted into 
HMI-9 or SDM-79 media (Brun et al., 1979) containing 5–50µM EGCG or DMSO 
control, and the culture cell densities were determined after 48 h. Values are 
expressed as a percentage of the DMSO control. For all panels, EGCG was 
prepared in filter-sterilized DMSO and used as a 100X stock. The mean of three 
replicates is shown. Error bars show SD. The * indicates p < 0.01 for the 
difference between DMSO and EGCG-treated conditions (Student’s t-test).  
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CHAPTER FIVE 
KNOCKDOWN OF Trypanosoma brucei ACYL-COA SYNTHETASE GENES 
BY RNA INTERFERENCE 
Patrick A. Vigueira and Kimberly S. Paul 
Department of Biological Sciences, Clemson University, Clemson, SC 
INTRODUCTION 
 
Acyl-CoA synthetases (ACS) are a class of enzymes that catalyze the 
thioesterification of free fatty acids (FA) to Coenzyme A (CoA). This process 
activates the fatty acids for use in metabolic processes (e.g., α/β-oxidation) and 
synthesis of phospholipids, cholesterol esters, ceramides and triglycerides 
(Watkins,1997; Soupene et al., 2008; Li et al., 2010). The irreversible, two-step 
ping-pong reaction occurs as follows. First, the FA is converted to an acyl-
adenylate, forming AMP and PPi from ATP. Second, the reaction is completed by 
esterification of the acyl-adenylate intermediate to CoA through hydrolysis of PPi, 
forming the final fatty acyl-CoA product (Watkins,1997; Li et al., 2010). 
The human genome codes for five long chain ACS genes (ACSL). The 
enzymes’ FA substrates include saturated and unsaturated species ranging from 
14-24 carbons. Each ACSL has a unique hierarchy of substrate preferences. 
However, many of their substrates overlap, creating redundancy in enzymatic 
activity (Soupene et al., 2008). Subcellular localization of the human ACSL1 and 
ACSL6 proteins are the best characterized. Both are located on the plasma 
membrane, and ACSL1 is tightly associated with fatty acid transport protein 1 
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(FATP1) in many cell types. The ACSL1/FATP1 interaction is believed to 
enhance FA uptake through vectorial acylation, the coordinated import and 
activation of FAs (Soupene et al., 2008).  
In addition to the annotated ACS genes, other proteins have been 
demonstrated to exhibit ACS activity. Mammalian FATP4 exhibits an intrinsic 
ACS activity and has been found to be involved in FA uptake. Despite being 
localized to the endoplasmic reticulum rather than the plasma membrane, 
expression of FATP4 was reported to correlate with increased fatty acid uptake. 
Increased fatty acyl-CoA retention is the proposed mechanism for this 
observation. While free FAs can diffuse across membranes and out of the cell, 
fatty acyl-CoAs are membrane impermeant and therefore cannot leave the cell 
by diffusion (Milger et al., 2006). 
The Trypanosoma brucei genome codes for 5 ACS genes based on 
homology to previously characterized genes for Leishmania ACS and yeast free 
fatty acid receptor 2. Each TbACS contains the characteristic ACS active site that 
controls FA binding and enzymatic specificity (Black et al., 1997; Jiang et al., 
2000; Smith et al., 2010). Sequence alignments of TbASC1-4 measured 46-95% 
similarity at the nucleotide level and 53-96% similarity at the protein level (Jiang 
et al., 2000). The TbASC1-4 genes are organized in a tandem array on 
chromosome 9 and the TbACS5 gene resides on chromosome 10 (Jiang et al., 
2000; Aslett et al., 2010). Northern blot analysis revealed that all TbACS1-4 
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genes are expressed in both bloodstream (BF) and procyclic (PF) form parasites 
(Jiang et al., 2000). 
 Recombinant versions of the TbACS1-4 genes have been expressed, 
purified, and assayed for ACS enzymatic activity (Jiang et al., 2001). TbACS1 
had preferences for saturated FAs C11:0 to C14:0. TbACS2 had the highest 
specificity, working mainly on C10:0 and C11:0. TbACS3 and TbACS4 had a 
very similar substrate preference, not surprisingly because of their 95% 
sequence identity; they accommodated a broad range of substrates and 
exhibited high affinity for saturated fatty acids C14:0 to C17:0. The substrate 
preference of TbACS5 has been less extensively characterized, but early studies 
suggest it has the highest affinity for C14:0 (Smith et al., 2010). TbACS1, 
TbACS3, and TbACS4 also exhibited high activity on a range of unsaturated FA 
substrates; however, TbACS2 activity was restricted to saturated fatty acids 
(Jiang et al., 2001). 
Here I present experiments that further the characterization of the TbACS 
genes. I investigated the collective functional role of the ACS genes in T. brucei 
FA uptake and growth. RNA interference (RNAi) of the TbACS genes in PF 
parasites had a profound effect on FA uptake and caused a minor reduction in 
parasite growth. 
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RESULTS 
Generation of panTbACS RNAi cell line 
Due to the high level of similarity among the TbACS genes, attempts to 
create an RNAi construct for single TbACS gene would likely be unsuccessful. 
Therefore, we elected to study the result of simultaneously knocking down all five 
of the currently-annotated TbACS genes. To do so, we chose a ~700-bp region 
with high homology among the TbACS genes. This region was amplified by PCR, 
cloned into the pZJM RNAi vector and stably transfected into PF parasites, 
creating a panTbACS RNAi cell line (Wang et al., 2000). 
Knockdown of TbACS reduced FA uptake 
In order to determine the effect of panTbACS RNAi on T. brucei FA 
uptake, cells were incubated with C12:0 or C16:0 FAs conjugated to a non-polar 
green fluorescent fluorophore (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene) (BODIPY), allowing FA uptake to be monitored by measuring cell-
associated fluorescence. Upon induction of RNAi, BODIPY-C12:0 (B-C12) and 
BODIPY-C16:0 (B-C16) FA uptake was assayed at 48 h intervals (Fig. 5.1). 
Induction of RNAi for 2 days caused a 34% reduction in B-C12 uptake (p <0.05) 
but had no effect on B-C16 uptake. B-C12 uptake was further reduced after 4 
days of RNAi to almost half of the uninduced control (47% reduction, p <0.01). 
This was accompanied by a 24% increase in B-C16 uptake (p <0.05). By day 6 of 
RNAi induction, B-C12 uptake was reduced further (58% reduction, p <0.01), 
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while B-C16 uptake was further increased by 48% relative to the uninduced 
control (p <0.01). 
Knockdown of TbACS reduced T. brucei growth. 
RNAi of panTbACS caused only a small reduction in growth over 6 days of 
induction (Fig. 5.2A). This reduction in growth was most evident in a comparison 
of cumulative cell densities at the 6-day time point (30% reduction, p <0.01) (Fig. 
5.2B).  Additionally, doubling time over the 6 days of panTbACS RNAi induction 
was increased by ~0.8 h (p <0.05) (Fig. 5.2C).  
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DISCUSSION 
Knockdown of the TbACS genes by RNAi caused a progressive reduction 
in uptake of B-C12 and a corresponding progressive increase in B-C16 uptake 
(Fig. 5.1). The former observation is likely due to reduced FA activation by 
TbACS, thereby reducing FA retention in the form of activated, membrane-
impermeant fatty acyl-CoAs.  
The increase in B-C16 uptake was somewhat unexpected and cannot be 
directly attributed to TbACS RNAi. We fully expected uptake of B-C12 and B-C16 
to respond similarly to TbACS RNAi because both FAs are highly suitable 
substrates for TbACS1, TbACS3, and TbACS4 (Jiang et al., 2001). It was clear 
that uptake efficiency was very different between the two chain lengths; B-C12 
was taken up at a rate ~10 times greater than B-C16 (data not shown). This was 
not unexpected, as B-C16 likely does not partition into the plasma membrane as 
efficiently due to its longer chain length. Additionally, the rate constant of the 
rate-limiting flip-flop reaction is decreased when FA chain lengths are increased 
(Kleinfeld et al., 1997). 
One possible explanation for the differential consequences of TbACS 
RNAi on B-C12 and B-C16 uptake is that the FAs are taken up through two 
distinct mechanisms. The parasite, sensing a reduction in FA acquisition due to 
TbACS knockdown compensated by up-regulating another FA uptake 
mechanism (currently undescribed in T. brucei). This could occur through 
increased expression or posttranslational modification of proteins involved in the 
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pathway. Assuming B-C12 enters the cell predominately through passive 
diffusion and subsequent activation by ACS and B-C16 is taken up primarily 
through the presumed upregulated mechanism, this could result in a net 
decrease in B-C12 uptake and increase in B-C16 uptake.      
These observations represent significant progress towards understanding 
the mechanisms of FA uptake in T. brucei. Based on kinetic experiments, it has 
long been suspected that the parasite’s FA uptake mechanisms mimic that found 
in mammals (Voorheis,1980). However, this is the first direct experimental 
evidence that FA uptake is mediated by multiple mechanisms in T. brucei. 
The reduction in parasite growth caused by 6 days of panTbACS RNAi 
induction was fairly mild (Fig. 5.2A). However, both cumulative cell density and 
doubling time showed statistically significant reductions after 6 days of 
panTbACS RNAi (Fig. 5.2B,C). This observation is in conflict with the previous 
report that TbASC5 is not essential for growth in either PF or BF parasites (Smith 
et al., 2010), however it is possible that no single TbACS gene is essential in 
isolation because the overlapping activities of the ACS family can compensate 
for the loss. 
It is also important to note that we detected changes in FA uptake prior to 
reduction in parasite growth. This suggests that the observed FA uptake 
phenotypes were likely a direct result of, or an immediate response to, TbACS 
knockdown and not due to non-specific complications associated with cell death.  
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FUTURE DIRECTIONS 
In the future, the panTbACS RNAi mutant should be tested for growth in 
low-lipid media and FA synthesis rates measured. Evidence from previously 
characterized genes involved in T. brucei FA metabolism demonstrates that the 
parasite is adaptable to changes in lipid availability. For example, the rate of fatty 
acid synthesis was increased when the parasites were cultured in low-lipid media 
(Lee et al., 2006). Additionally, RNAi mutants for genes involved in FA synthesis 
only exhibited a growth phenotype when cultured in low-lipid media (Lee et al., 
2006; Vigueira et al., 2011). I anticipate that FA synthesis will be upregulated due 
to the parasite’s reduced capacity to acquire FA from the environment. 
 In addition to causing a reduction in B-C12 uptake, presumably TbACS 
knockdown also reduced the activation of FAs to CoA esters. This reduction 
could be quantified using high-performance liquid chromatography. Because FAs 
require activation in order to be incorporated into more complex lipid species, I 
anticipate that TbACS knockdown will also lead to an increase in the levels of 
free FAs in the parasite. This could be examined by labeling parasites with 
[3H]C12:0 and measuring incorporation into complex lipids using densitometric 
analysis of total cellular lipid content resolved by thin layer chromatography.  
One likely and potentially exciting consequence of panTbACS knockdown 
is the reduction in glycophosphatidylinositol (GPI) anchor synthesis. BF T. brucei 
depends on the production of copious amounts of a dimyristoyl GPI anchor to 
attach its dense surface coat (107 copies per cell) to the plasma membrane. The 
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variant surface glycoprotein coat is critical to the parasites ability to evade the 
adaptive immune system, and therefore perturbations in the GPI biosynthesis 
pathway could compromise the parasites virulence in the mammalian host. This 
highlights the importance of extending my studies of TbACS into BF parasites.   
 Protein modifications by acetylation are also important to the survival of 
the parasite. Recently, N-myristoylation has been validated as a drug target. The 
myristoyl-CoA:protein N-myristoyltransferase (NMT) is essential for virulence in a 
mouse model (Price et al., 2010). The TbACS genes are potentially involved in 
generating the myristoyl-CoA used by NMT and could therefore represent drug 
targets. 
 I have provided the first glimpse into the role of ACS in T. brucei’s FA 
uptake pathway. However, my studies have barely scratched the surface of what 
can be learned about these genes. Many experimental questions pertaining to 
TbACS remain unasked. I hope that this work and my thoughts provide a future 
Paul Lab student the opportunity to extend our knowledge of these exciting 
genes. 
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MATERIALS AND METHODS 
Trypanosome strains, cell lines, and media 
PF T. brucei transgenic cell lines containing genomically integrated 
Tetracycline (TET) repressor and T7 polymerase [29-13 (Wirtz et al., 1999)] were 
generously provided by Dr. George Cross (Rockefeller University). PF parasites 
were grown in SDM-79 medium (Brun et al., 1979) containing 10% heat-
inactivated FBS and supplemented with 15 mg/ml  G418, 50 mg/ml  hygromycin 
and 2.5 mg/ml  phleomycin.  
 
Generation of panTbACS RNAi cell line 
To make the panTbACS RNAi construct, an ~700-bp fragment containing 
a highly homologous region among  the TbACS genes was amplified by PCR 
from WT 427 PF genomic DNA using a forward primer containing a 5′ XhoI site 
(5′-ctcgagTACTGCGCTTACCTGC-3′) and a reverse primer containing a 5′ 
HindIII site (5′-aagcttGCCAATGATGCGAAGGGT-3′). This amplicon was first 
cloned into pCR2.1 TOPO prior to subcloning into the TET-inducible RNAi vector 
pZJM (Wang et al., 2000). The resulting pZJM.panTbACS plasmid was 
confirmed by sequencing.  
The pZJM.panTbACS plasmid DNA was isolated from 10 mL of overnight 
Escherichia coli culture using 2 QIAprep Miniprep columns (Qiagen). 100 µL of 
the purified plasmid DNA was linearized in a 200 µL restriction digest containing 
20 U of Not1 restriction enzyme (New England Biolabs) for 3 h at 37° C. The 
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linearized DNA was then cleaned up using 2 MinElute Reaction Cleanup 
columns (Qiagen). Linearized DNA was eluted from the columns in warm sterile 
H2O and quantified using a BioPhotometer spectrometer (Eppendorf). 
 For transfection, 1x108 PF 29-13 parasites were harvested by 
centrifugation (10 min, 2500 x G). The parasites were then resuspended in 500 
µL of prewarmed Cytomix (van den Hoff et al., 1992) and mixed with 20 µg of 
linearized pZJM.panTbACS. A mock transfection that included H2O rather than 
DNA was prepared to ensure proper drug selection. The cells were then 
electroporated in a 4 mm gap cuvette under the following conditions: exponential 
decay mode, 2 pulses with a 10 second interval, capacitance 25 µF, voltage 
1.5kV (Djikeng et al., 2004). The cells were then transferred to 40 mL of 
prewarmed SDM-79 containing G418 and hygromycin. Phleomycin was added to 
the cultures 18 h later to select for successful transfectants. Following drug 
selection, clonal populations were established by limiting dilution.      
In vitro Growth Experiments 
For growth curves, panTbACS RNAi cells were diluted into SDM-79 
media, induced for RNAi by the addition of TET (1 mg/ml final) (Wang et al., 
2000). Cell density was monitored using a FACScan flow cytometer 
approximately every 48 h (Becton Dickinson). For comparison purposes, 
doubling times were calculated for each experimental condition. Following each 
cell count, cultures were diluted to maintain logarithmic phase growth. 
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Fatty Acid Uptake 
FA uptake was monitored at approximately 48 h intervals. To assay FA 
uptake, cells were incubated for 20 min at room temperature in a solution of 50% 
SDM-79 and 50% Cytomix containing 20 µM B-C12 or B-C16. Following the 
incubation, 300 µL of ice-cold Cytomix was added and tubes were chilled on ice 
for 2 min. Cells were then washed by centrifugation (2 min, 8000 x g) and 
resuspension in Cytomix. Cell-associated fluorescence was measured using a 
FACScan flow cytometer (Becton Dickinson). The values were corrected for 
background fluorescence by subtracting values collected from an unstained 
population of cells. Final values are expressed as a percentage of the uninduced 
control. 
Statistics 
 One-tailed Student’s t-test analyses between control and treatments were 
performed using Microsoft Excel. We judged statistical significance to be p < 
0.05. Error bars represent standard deviation from the mean. 
 160
FIGURES 
Figure 5.1: Effect of panTbACS RNAi on T. brucei FA Uptake. PF panTbACS 
RNAi parasites were grown in uninduced (no RNAi) or induced (panTbACS 
RNAi) conditions and assayed for uptake of B-C12 (A) and B-C16 (B) every other 
day for 6 days. All values are expressed as a percentage of the uninduced 
control. For both panels, the mean of three replicates is shown. Error bars show 
SD. The * indicates p < 0.05 and ** indicates p < 0.01   for the difference 
between uninduced and induced RNAi conditions, Student’s t-test. 
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Figure 5.2: Effect of panTbACS RNAi on in vitro growth of T. brucei. PF 
panTbACS RNAi parasites were grown in uninduced (no RNAi) or induced 
(panTbACS RNAi) conditions and cell densities of the cultures were recorded 
every other day for 6 days. A. Cumulative culture densities over 6 days. B. Final 
cumulative culture densities after 6 days. C. Parasite doubling times.  For all 
panels, the mean of three replicates is shown. Error bars show SD. Please note 
in A, error bars are too small to be visible. The * indicates p < 0.05 and ** 
indicates p < 0.01   for the difference between uninduced and induced RNAi 
conditions, Student’s t-test. 
 
 
 162
REFERENCES  
Aslett M., Aurrecoechea C., Berriman M., Brestelli J., Brunk B.P., Carrington M., 
et al. (2010) TriTrypDB: A functional genomic resource for the 
Trypanosomatidae. Nucleic Acids Res 38: D457-62. 
Black P.N., Zhang Q., Weimar J.D., and DiRusso C.C. (1997) Mutational analysis 
of a fatty acyl-coenzyme A synthetase signature motif identifies seven 
amino acid residues that modulate fatty acid substrate specificity. J Biol 
Chem 272: 4896-4903. 
Brun R., and Schonenberger M. (1979) Cultivation and in vitro cloning of 
procyclic culture forms of Trypanosoma brucei in a semi-defined medium. 
Acta Trop 36: 289-292. 
Djikeng A., Shen S., Tschudi C., and Ullu E. (2004) Analysis of gene function in 
Trypanosma brucei using RNA interference. In Parasite Genomics 
Protocols. Melville, S.E. (ed). Totowa, New Jersey: Humana Press, pp. 
287. 
Jiang D.W., and Englund P.T. (2001) Four Trypanosoma brucei fatty acyl-CoA 
synthetases: Fatty acid specificity of the recombinant proteins. Biochem J 
358: 757-761. 
Jiang D.W., Ingersoll R., Myler P.J., and Englund P.T. (2000) Trypanosoma 
brucei: Four tandemly linked genes for fatty acyl-CoA synthetases. Exp 
Parasitol 96: 16-22. 
Kleinfeld A.M., Chu P., and Romero C. (1997) Transport of long-chain native fatty 
acids across lipid bilayer membranes indicates that transbilayer flip-flop is 
rate limiting. Biochemistry 36: 14146-14158. 
Lee S.H., Stephens J.L., Paul K.S., and Englund P.T. (2006) Fatty acid synthesis 
by elongases in trypanosomes. Cell 126: 691-699. 
Li L.O., Klett E.L., and Coleman R.A. (2010) Acyl-CoA synthesis, lipid 
metabolism and lipotoxicity. Biochim Biophys Acta 1801: 246-251. 
Milger K., Herrmann T., Becker C., Gotthardt D., Zickwolf J., Ehehalt R., et al. 
(2006) Cellular uptake of fatty acids driven by the ER-localized acyl-CoA 
synthetase FATP4. J Cell Sci 119: 4678-4688. 
Price H.P., Guther M.L., Ferguson M.A., and Smith D.F. (2010) Myristoyl-
CoA:Protein N-myristoyltransferase depletion in trypanosomes causes 
avirulence and endocytic defects. Mol Biochem Parasitol 169: 55-58. 
 163
Smith T.K., and Butikofer P. (2010) Lipid metabolism in Trypanosoma brucei. Mol 
Biochem Parasitol 172: 66-79. 
Soupene E., and Kuypers F.A. (2008) Mammalian long-chain acyl-CoA 
synthetases. Exp Biol Med (Maywood) 233: 507-521. 
van den Hoff M.J., Moorman A.F., and Lamers W.H. (1992) Electroporation in 
'intracellular' buffer increases cell survival. Nucleic Acids Res 20: 2902. 
Vigueira P.A., and Paul K.S. (2011) Requirement for acetyl-CoA carboxylase in 
Trypanosoma brucei is dependent upon the growth environment. Mol 
Microbiol 80: 117-132. 
Voorheis H.P. (1980) Fatty acid uptake by bloodstream forms of Trypanosoma 
brucei and other species of the kinetoplastida. Mol Biochem Parasitol 1: 
177-186. 
Wang Z., Morris J.C., Drew M.E., and Englund P.T. (2000) Inhibition of 
Trypanosoma brucei gene expression by RNA interference using an 
integratable vector with opposing T7 promoters. J Biol Chem 275: 40174-
9. 
Watkins P.A. (1997) Fatty acid activation. Prog Lipid Res 36: 55-83. 
Wirtz E., Leal S., Ochatt C., and Cross G.A. (1999) A tightly regulated inducible 
expression system for conditional gene knock-outs and dominant-negative 
genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89-101. 
 
 164
CHAPTER 6 
A FORWARD-GENETIC SCREEN FOR GENES INVOLVED IN Trypanosoma 
brucei FATTY ACID UPTAKE 
Patrick A. Vigueira, Marianne M. Ligon, Ben A. Martin and Kimberly S. Paul 
Department of Biological Sciences, Clemson University, Clemson, SC 
INTRODUCTION 
In both procyclic (PF) and bloodstream (BF) life stages Trypanosoma 
brucei relies on dense glycoprotein surface coats for survival. Procyclin covers 
the PF parasite and is believed to protect the parasite from proteolytic 
degradation while in the midgut of the tsetse (Richardson et al., 1988; Roditi et 
al., 1989). The BF form relies on variant surface glycoprotein (VSG) to evade the 
mammalian host’s adaptive immune system (Horn et al., 2010). Both procyclin 
(106 copies per cell) and VSG (107 copies per cell) are very densely arranged on 
the cells surface. Each glycoprotein is attached to the parasite’s outer membrane 
by specialized glycolipids called glycosylphosphatidylinositol (GPI) anchors, each 
including two fatty acid (FA) moieties. The high density of essential, GPI-
anchored surface coat proteins imposes a tremendous requirement for FAs.  
The parasite has two options for satisfying its requirement for FAs: 
synthesis or uptake. Evidence from previous studies suggests that FA uptake is 
preferred over synthesis (Doering et al., 1993; Lee et al., 2006; Vigueira et al., 
2011). Compared to FA synthesis, uptake is highly energetically favorable. For 
example, a C16:0 FA that diffuses into a cell and is subsequently activated by 
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esterification to a Coenzyme A (CoA) molecule requires the hydrolysis of a single 
ATP. In comparison, synthesis of the same C16:0 FA de novo would require 6 
ATPs and 12 NADH/NADPH reducing equivalents (Morita et al., 2000; Lee et al., 
2006; Stephens et al., 2007). Despite their importance in the FA metabolism of 
the parasite, little is known about the mechanisms or genes involved in T. brucei 
FA uptake. I therefore set out to conduct an RNA interference (RNAi)-based 
genetic screen to identify genes involved in T. brucei FA uptake.  
The creation of an RNAi library by a group of visionary scientists opened 
the door to forward-genetic experiments in T. brucei (Morris et al., 2002). The 
library was created by cloning sheared fragments of T. brucei genomic DNA 
(gDNA) into the pZJM RNAi vector (Wang et al., 2000). The resulting plasmid 
library was then stably transfected into procyclic form (PF) parasites. The 
coverage of the RNAi library is ~5 fold (Morris et al., 2002; Morris et al., 2005; 
Alsford et al., 2011). Thus, upon expansion of the library, each gene in genome 
should be represented by multiple parasites. The library has proven to be a 
useful tool in identifying novel parasite genes and revealing uncharacterized 
biological functions of described genes (Morris et al., 2002; Drew et al., 2003; 
Zhao et al., 2008). 
To measure FA uptake we utilized a commercially available FA 
conjugated to a non-polar green fluorescent fluorophore (4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene) (BODIPY). BODIPY-FAs have been 
previously validated as useful tools for the study of FA uptake (Li et al., 2005) 
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and exhibit properties very similar to unlabeled fatty acids (Zou et al., 2003; 
Thumser et al., 2007; Hostetler et al., 2010). Previous studies in our lab have 
also validated BODIPY-FAs for use in T. brucei. Cell associated fluorescence 
increases with incubation time and FA concentration. My studies of the T. brucei 
acyl-CoA synthetases (Chapter 5) demonstrated that RNAi of known FA uptake 
genes reduced uptake of BODIPY-C12:0 (B-C12), further validating the basis of 
the screen.  
In brief, following 4 days of RNAi induction, the library population of cells 
were incubated with B-C12 and the dim parasites (those taking up less FA) were 
isolated using fluorescence activated cell sorting. Dim parasites were then 
subjected to a second round of RNAi induction and FA uptake screening. Clones 
with the lowest capacity for uptake were expanded and the RNAi insert was 
identified by PCR amplification and subsequent sequencing. Many genes were 
identified, but an initial attempt to validate the role of these genes in FA uptake 
was unsuccessful. Here I describe the screen in detail and offer suggestions for 
future work and screens. 
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MATERIALS AND METHODS 
 
Primary FA Uptake Screen 
The T. brucei 660-bp RNAi library was thawed from six 1 mL liquid 
nitrogen stabilates and allowed to expand for 2 days. In order to achieve the 
theoretical 5-fold genome coverage, 200 µL of the expanded RNAi library culture 
were seeded into 4 mL of fresh SDM-79 media. Induction of RNAi was initiated 
by addition of 1 mg/mL tetracycline (TET) to the media (Wang et al., 2000). The 
culture volume was expanded as needed to maintain logarithmic growth, but no 
dilutions were made. Following 4 days of RNAi induction, 5 mL of culture 
(6.3x106 cells/mL) were utilized for fluorescence activated cell sorting.  
 The parasites were incubated for 20 min at room temperature in a solution 
of 50% SDM-79 and 50% Cytomix (van den Hoff et al., 1992) containing 20 µM 
B-C12. Following the incubation, cells were washed twice by centrifugation (2 
min, 8000 x g) and resuspension in Cytomix. Cell sorting was conducted in the 
Clemson University Cell Analysis Laboratory by the lovely and talented Dr. 
Meredith Morris using the Cytopeia Influx fluorescence-activated cell sorter. The 
parasites were analyzed using a dot plot (yellow channel, Y-axis and green 
channel, X-axis) and gated for normal cellular morphology using the forward and 
side scatter detectors. Parasites in the dimmest 1% of the population were 
distributed into individual wells of 96-well plates. In total, sixty 96-well plates were 
collected.  
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Secondary FA Uptake Screen 
 The 96-well plates were monitored daily for parasite growth. After ~2 
weeks of incubation, parasites that had grown to density were diluted into fresh 
media in ten 96-well plates. These clonal populations were then subjected to a 
second round of screening to further isolate clones that exhibited the strongest 
FA uptake phenotype. Prior to RNAi induction, replica plates were generated to 
maintain uninduced cell populations for further analysis. RNAi was induced for 4 
days prior to FA uptake analysis using a Guava Flow Cytometer. In an attempt to 
maximize the dynamic range of the FA uptake assay, cells were incubated with 
40 µM B-C12, double the concentration used in the original sort. Following 20 
min of incubation, the cells were transferred to a 30 µM filter plate (Millipore) 
positioned above a v-bottom 96-well plate. The plates were centrifuged at 4° C 
for 10 min at a speed of 3200xG. As the cultures passed through the filter plate, 
cellular aggregations were eliminated and individual cells pelleted in the v-bottom 
96-well plate. The staining solution was removed by aspiration, and parasites 
were resuspended in 200 µL Cytomix. Histogram plots of cell-associated 
fluorescence were generated using the 408 nm (yellow channel) detector. The 
geometric means of each histogram were used to determine the dimmest 24 
clones from each of the ten 96-well plates. The corresponding clonal populations 
were transferred from the replica plates into ten 24-well plates for culture 
expansion.   
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PCR and Sequencing 
 gDNA was purified from each of the expanded clonal populations using an 
STE buffer protocol. Parasites were harvested from 1 mL of dense culture by 
centrifugation (3 min, 8,000xG), washed once in Cytomix and resuspended in 
200 µL of STE buffer (10 mM Tris-HCl, 1 mM EDTA and 100 mM NaCl). The cell 
suspension was then incubated for 10 min in a 95° C heat block and transferred 
to ice for 5 min. The lysed cells were then subjected to RNAse treatment (125 
µg/mL) for 5 min in a 37° C thermomixer at a speed of 500 RPM. Proteins were 
then degraded by proteinase K treatment (250 µg/mL) for 15 min in a 60° C 
thermomixer at a speed of 500 RPM. The RNAse and proteinase K were 
subsequently inactivated by heating the samples for 5 min in a 95° C heat block. 
Following a 5 min incubation on ice, cellular debris was removed by 
centrifugation (5 min, 16,000xG).  
To determine the gene responsible for causing reduction in FA uptake, the 
pZJM insert was amplified from the gDNA using a nested PCR approach 
described previously (Morris et al., 2005). The first PCR contained 5 µL of GoTaq 
Colorless Mastermix (Promega), 1 µL of each primer PhleoF and AldoR (Morris 
et al., 2005) (diluted 1:10 in sterile H2O), 1 µL of freshly-purified gDNA, and 2 µL 
of sterile H2O. Thermocycling conditions were as follows: initial denaturation, 94° 
C for 2 min; 40 cycles of denaturation, 94° C for 20 sec, annealing, 55° C for 30 
sec, extension, 72° C for 2.5 min; final extension 72° C for 5 min. The second 
PCR using the internal primers contained 10 µL of GoTaq Colorless Mastermix, 1 
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µL of each primer XlinkF and BetaLow (Morris et al., 2005) (diluted 1:10 in sterile 
H2O), 1 µL of PCR product from the first reaction and 7 µL of sterile H2O. 
Thermocycling conditions were as follows: initial denaturation, 94° C for 2 min; 40 
cycles of denaturation, 94° C for 20 sec, annealing, 61° C for 30 sec, extension, 
72° C for 2.5 min; final extension 72° C for 5 min. The PCR products were then 
subjected to DNA electrophoresis on a 1% w/v agarose gel. The quantity and 
purity of the PCR products were assessed by examining the size and number of 
bands from each reaction. Reactions that contained a single product were 
prepared for direct sequencing. 
In order to perform direct sequencing on PCR products, the primers used 
in the PCR must be removed. This was accomplished by treatment with 
Exonuclease I and Antarctic Phosphatase (exo-AP) (Fisher). A working stock of 
exo-AP was prepared by diluting Exonuclease I 1:100 and Antarctic Phosphatase 
1:10 in sterile H2O. 1 µL of each PCR product was combined with an equal 
volume of the exo-AP enzyme mixture. Samples were then incubated at a 
temperature of 37ºC for 30 min and subsequently 80ºC for 15 min.  
Following exo-AP treatment, 1 µL of XlinkF primer (diluted 1:10 in sterile 
H2O) was added to each sample. PCR products determined to be larger than 
1000 bp by DNA electrophoresis were included in a second sequencing reaction 
using the BetaLow primer. Sequencing reactions were performed by the 
Clemson University Genomics Institute (CUGI). Sequencing results were 
analyzed using Sequencher (Gene Codes) and trimmed manually to include only 
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high quality sequence. The TriTryp database was utilized to perform BLAST 
searches against the T. brucei strain 927 genome (Aslett et al., 2010).  
RNAi Cell Line Generation 
Four genes were chosen to rebuild RNAi constructs for uptake phenotype 
verification: Tb927.7.1310, Tb927.7.6550, Tb11.47.0009, and Tb927.10.14430 
identified from clones 1F11, 3B12, 5F10, 6G5, respectively. Primers were 
designed to amplify ~ 500 bp region from each of the genes.  These genes 
fragments were amplified by PCR from wild-type PF 427 genomic DNA using a 
forward primer containing a 5′ XhoI site and a reverse primer containing a 5′ 
HindIII. Each primer also included 4 additional 5’ nucleotides to allow direct 
digestion of PCR products. The primer sequences for each gene are as follows: 
Tb927.7.1310, pv1F11f.XhoI 5’ –GATCctcgagCGGAGCATCCTAACCAACAG – 
3’ and pv1F11r.HindIII 5’ – GATCaagcttTCCCAGGACCAGCCGGAGCG – 3’; 
Tb927.7.6550, pv3B12f.XhoI 5’ –GATCctcgagCCATTCTGTGCAATGTGGGG – 
3’ and pv3B12r.HindIII 5’ – GATCaagcttTCAAGGTCTCGGTGATGTTG – 3’; 
Tb11.47.0009, pv5F10f.XhoI 5’ –GATCctcgagCCTCACGGAGTGTATTAAAC– 3’ 
and 5F10r.HindIII 5’ – GATCaagcttCAGCCCGAACAACCGGTGAG – 3’; 
Tb927.10.14430, pv6G5f.XhoI 5’ – ATCctcgagGGTGGGAATCACCGAGATTG– 
3’ and pv6G5r.HindIII 5’ – GATCaagcttCGTGATGTTGTCGCACGACG – 3’. 
Following a restriction digest with XhoI and HindIII, the amplicons were ligated 
into the TET-inducible RNAi vector pZJM. The resulting plasmids were confirmed 
by sequencing.  
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Each RNAi construct plasmid was isolated from 10 mL of overnight 
Escherichia coli culture using 2 QIAprep Miniprep columns (Qiagen). 100 µL of 
the purified plasmid DNA was linearized in a 200 µL restriction digest containing 
20 U of Not1 restriction enzyme (New England Biolabs) for 3 h at 37° C. The 
linearized DNA was then cleaned up using 2 MinElute Reaction Cleanup 
columns (Qiagen). Linearized DNA was eluted from the columns in warm sterile 
H2O and quantified using a BioPhotometer spectrometer (Eppendorf). For 
transfection 1x108 PF 29-13 parasites were harvested by centrifugation (10 min, 
2500 x G). The parasites were then resuspended in 500 µL of prewarmed 
Cytomix and mixed with 20 µg of linearized RNAi construct. A mock transfection 
that included water rather than DNA was prepared to ensure proper drug 
selection. The cells were then electroporated in a 4 mm gap cuvette under the 
following conditions: exponential decay mode, 2 pulses with a 10 second interval, 
capacitance 25 µF, voltage 1.5kV (Djikeng et al., 2004). Following 
electroporation, the cells were transferred to 40 mL of prewarmed SDM-79 
containing G418 and hygromycin. Phleomycin was added to the cultures 18 h 
later to select for successful transfectants.  
Fatty Acid Uptake Experiments 
FA uptake was monitored at 2 or 4-day intervals. To assay FA uptake, 
cells were incubated for 20 min at room temperature in a solution of 50% SDM-
79 and 50% Cytomix containing 20 µM B-C12. Cells were then washed by 
centrifugation (2 min, 8000 x g) and resuspension in Cytomix. Cell-associated 
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fluorescence was measured using a FACScan flow cytometer (Becton 
Dickinson). The values were corrected for background fluorescence by 
subtracting values collected from an unstained population of cells. Alternatively, 
cells were incubated for 10 min at room temperature in a solution of 50% SDM-
79 and 50% Cytomix containing 20 µM [3H]-C12. Cells were then washed twice 
by centrifugation (2 min, 8000 x g) and resuspension in Cytomix. Cell-associated 
radioactivity was measured using an LS-6500 liquid scintillation counter (Becton 
Dickinson). Final values are expressed as a percentage of the uninduced or 29-
13 control. 
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RESULTS 
In total, BLAST searches identified 99 clones containing pZJM inserts with 
high homology to annotated genes from the T. brucei strain 927 genome (Table 
6.1). 12 genes were represented multiple times (Table 6.2). One gene, 
Tb927.4.1320, was particularly enriched, identified from 32 clones. 
I independently assessed 4 of the clonal cell lines (3B12, 3C4, 5B6, 6G5) 
for reduced FA uptake following 4 and 6 days of RNAi induction (Fig. 6.2). These 
clones were particularly interesting because they contained predicted 
transmembrane domains and/or signal peptides, both features of proteins 
involved in FA uptake in other organisms. Compared to uninduced controls, only 
clone 3B12 exhibited reduced FA uptake on day 4 and 6 of induction. However, 
each of the clones exhibited greater than 40% reduction in uptake when 
compared to the parental 29-13 control.   
Based on the predicted attributes of the genes identified by BLAST 
searches, we chose 4 candidates we were interested in further characterizing 
(1F11, 3B12, 5F10, 6G5). To generate independent RNAi cell lines for each 
candidate gene I cloned a new target sequence that was different from the 
original target sequence in the RNAi library into pZJM. Induction of RNAi for 8 
days resulted in a 41% reduction in uptake of B-C12 in the pv5F10 cell line (Fig. 
6.3B). This reduction in uptake was accompanied by a 56% reduction in growth 
(data not shown). RNAi induction in the remaining 3 cones (pv1F11, pv3B12, 
pv6G5) did not reduce B-C12 uptake relative to the uninduced controls (Fig. 6.3).  
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DISCUSSION AND FUTURE DIRECTIONS 
 
 The two most common genes isolated from the screen were Tb927.4.1320 
(32 hits) and Tb11.02.2810 (17 hits), both annotated as conserved hypothetical 
proteins. According to the InterPro protein analysis and classification database, 
Tb927.4.1320 contains a SMAD/FHA domain and Tb11.02.2810 contains an 
RNA-binding domain. Thus, both genes are likely involved in gene expression. 
While knockdown of these genes may cause reduction in FA uptake, they are of 
limited interest to this project because it is unlikely that they are directly involved 
in FA uptake. Most likely, these genes cause broad changes in gene expression 
that, among other effects, reduces FA uptake.  
 The screen yielded many potentially interesting genes that should be 
independently characterized in the future. For the initial follow-up experiments, I 
used a fairly loose set of criteria for prioritizing interest in genes. Genes that 
contained predicted transmembrane domains were considered high priority 
because many FA uptake genes in other organisms code for integral membrane 
proteins. Genes with predicted signal peptides were also of particular interest 
because many FA uptake proteins are localized to the cell membrane or 
endoplasmic reticulum, both destinations of the secretory pathway. 
It is very curious and somewhat disturbing that neither the isolated clones 
nor the rebuilt RNAi mutants exhibited consistently reduced FA uptake. Because 
we selected the dimmest 1% of the population in the primary sort and then 
further narrowed the candidates by 75% in the secondary screen, we should 
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have isolated the dimmest 0.25% of the RNAi library at 4 days of RNAi induction. 
However, when the clones or genes are tested independently and compared to 
uninduced controls, I observed no consistent reductions in FA uptake. It is 
difficult to reconcile this observation with the methodology of the screen.  
In the 4 tested clones, [3H]-C12 uptake was consistently reduced when 
induced RNAi conditions were compared to 29-13 parental controls, but not 
uninduced controls (Fig. 6.2). This could potentially be explained by leaky 
expression of dsRNA in the uninduced controls, causing a constant induction of 
RNAi in the absence of TET in the media. Theoretically, uninduced RNAi mutants 
should exhibit phenotypes identical to that of the 29-13 parental parasites, but in 
this experiment they do not.  This could potentially result in an apparent 
dampening or masking of the phenotype upon induction. Leaky expression did 
not impact the primary or secondary screen because I did not select clones 
based on comparison to uninduced controls. Instead, I chose clones exhibiting 
low B-C12 uptake under induced RNAi conditions. 
Another possibility is that we selected for clones that were deficient in FA 
uptake on the basis of the location of the RNAi vector integration rather that the 
RNAi target gene fragment. Typically, linearization of the RNAi construct plasmid 
by Not1 restriction digest results in integration into the transcriptionally-inactive 
ribosomal spacer region. However, errant integration into alternative genomic loci 
could cause the disruption of non-target genes and influence gene-expression 
patterns in the surrounding regions. This concept has been demonstrated 
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previously (Motyka et al., 2004). This phenomenon has the potential to create 
parasites that are deficient in FA uptake and not responsive to RNAi. This is 
consistent with my observation that each of the isolated clones exhibited reduced 
FA uptake compared to parental 29-13 parasites (Fig. 6.2). 
Future screens should avoid this potential problem by using an alternative 
methodology for the secondary screen. Rather than utilizing the secondary 
screen to select for the dimmest clones, one should compare the uptake of 
induced and uninduced RNAi clones. The clones with the greatest reduction in B-
C12 uptake compared to uninduced controls should be maintained for further 
screening. This will help to ensure that the reduced uptake phenotype is a result 
of RNAi of the target gene rather than gene disruptions due to errant RNAi 
construct integration.           
Of the four genes I chose to target with independently constructed RNAi 
vectors, only pv5F10 caused a reduction in B-C12 uptake (Fig. 6.3). Clone 5F10 
isolated from the screen targeted Tb11.47.0009, annotated as a conserved 
hypothetical protein in the TriTryp database. The sequence codes for a protein 
with a predicted molecular weight of ~94kD and contains no predicted signal 
peptides or transmembrane domains. However, it was of interest to this screen 
because it contains a peroxisomal targeting signal and is therefore predicted to 
be localized to the glycosome, though it was not included in the report of 
glycosome proteomics (Colasante et al., 2006). It is also important to note that 
RNAi of Tb11.47.0009 caused a reduction in parasite growth (data not shown). 
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While I have demonstrated that RNAi of genes involved in FA uptake can 
potentially cause a slowed-growth phenotype (Chapter 5), it is possible that in the 
case of Tb11.47.0009, reduced FA uptake was a consequence rather than a 
cause of unhealthy cells. Both the reduced FA uptake and growth phenotypes 
became apparent following 8 days of pv5F10 RNAi induction, but neither was 
detected on day 4. Thus, future studies should include an additional time point at 
6 days post-induction to determine which of the phenotypes (reduced uptake or 
growth) are exhibited first.  
Despite not exhibiting an uptake phenotype, the independently 
constructed RNAi cell lines I have generated (pv1F11, pv3B12, pv6G5) should 
not be abandoned. The experiments I have presented in this chapter represent a 
single experiment using non-clonal cell lines. Clonal cell lines should be 
established for each mutant, and the resulting cell lines should be used to repeat 
the uptake experiments I have described. In addition, the efficiency of RNAi 
knockdown has not been assessed in any of the discussed cell lines.  
Recognizing the shortcomings of this RNAi screen, there remains great 
potential to find genes involved in FA uptake from the data we have generated. 
Within the list there are a number of interesting candidates currently annotated 
as hypothetical proteins. These genes should be targeted by conducting FA 
uptake and growth assays with independently constructed RNAi mutant cell lines. 
Sequencing of RNAi target genes from many of the dim clones was either not 
attempted or proved unsuccessful. However, I created liquid nitrogen stabilates 
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for all of the clones selected in the secondary screen, so they are available for 
further analysis when funding becomes available.  
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TABLES AND FIGURES 
 
Table 6.1: FA Uptake Screen Results. Gene annotations, TriTryp gene IDs, 
BLAST fragment homology scores, predicted signal peptides (SP) and 
transmembrane domains (TMD) from the clones isolated in the FA uptake 
screen. 
Clone ID Gene Annotation TriTryp Gene ID BLAST Homology Score SP, TMD
up1A1 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1A8 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1B3 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1B12 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1C6 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1C10 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1D7 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1E10 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1E12 hypothetical protein, conserved Tb11.01.0950 Positives = 856/1105 (77%)
up1F3 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1F11 hypothetical protein, conserved Tb927.7.1310 Positives = 471/491 (95%)
up1G1 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1G2 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1G3 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up1G5 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up1G8 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up2A6 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up2A8 hypothetical protein, conserved Tb927.4.1320 Positives = 293/364 (80%)
up2C6 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up2D3 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up2D6 hypothetical protein, conserved Tb11.02.2810 Positives = 287/360 (79%)
up2E2 hypothetical protein, conserved Tb11.01.0950 Positives = 679/710 (95%)
up2E3 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up2E8 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up2F2 hypothetical protein, conserved Tb11.01.0950 Positives = 679/710 (95%)
up2F4 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up2F6 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up2G5 hypothetical protein, conserved Tb927.4.1320 Positives = 261/336 (77%)
up2H2 hypothetical protein, conserved Tb11.02.2810 Positives = 282/332 (84%)
up2H3 hypothetical protein, conserved Tb927.4.1320 Positives = 258/335 (77%)
up2H8 hypothetical protein, conserved Tb927.4.1320 Positives = 176/197 (89%)
up3A3 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up3B12 hypothetical protein, conserved Tb927.7.6550 Positives = 524/615 (85%) SP, 1 TMD
up3C4 hypothetical protein, conserved Tb927.7.6550 Positives = 567/614 (92%) SP, 1 TMD
up3C7 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up3D9 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up3E1 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up3E9 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up3F2 hypothetical protein, conserved Tb927.4.1320 Positives = 306/379 (80%)
up3F5 hypothetical protein, unlikely Tb927.1.200 Positives = 139/196 (70%) 2 TMDs
up3F6 hypothetical protein, conserved Tb11.02.2810 Positives = 319/332 (96%)
up3F9 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up3G2 EP1 procyclin Tb927.10.10260 Positives = 127/175 (72%) 
up3G10 hypothetical protein, unlikely Tb09.160.1350 Positives = 104/143 (72%) 1 TMD  
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Clone ID Gene Annotation TriTryp Gene ID BLAST Homology Score SP, TMD
up4A2 hypothetical protein, unlikely Tb927.1.200 Positives = 118/149 (79%) 2 TMDs
up4B4 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4B6 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4B10 hypothetical protein, unlikely Tb09.160.1350 Positives = 93/143 (65%) 1 TMD
up4C4 hypothetical protein, unlikely Tb927.1.460 Positives = 82/116 (70%) 2 TMDs
up4C10 hypothetical protein, unlikely Tb927.1.460 Positives = 84/118 (71%) 2 TMDs
up4D4 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4D11 hypothetical protein, unlikely Tb927.1.200 Positives = 61/93 (65%) 2 TMDs
up4E6 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4F7 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4G2 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4G8 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
up4H11 hypothetical protein, conserved Tb927.4.1320 Positives = 378/378 (100%)
up4H12 hypothetical protein, conserved Tb927.4.1320 Positives = 349/378 (92%)
up5B6 hypothetical protein, conserved Tb11.18.0010 Positives = 95/107 (88%) SP, 7 TMDs
up5D2 DNA topoisomerase ii Tb09.160.4090 Positives = 501/522 (95%)
up5E8 hypothetical protein, conserved Tb927.5.700 Positives = 756/885 (85%)
up5E10 hypothetical protein, conserved Tb11.01.5780 Positives = 227/282 (80%)
up5F10 hypothetical protein, conserved Tb11.47.0009 Positives = 840/895 (93%) 
up5G5 hypothetical protein, conserved Tb11.01.5780 Positives = 251/251 (100%)
up6A10 hypothetical protein, conserved Tb11.01.6610 Positives = 294/327 (89%), 
up6D10 hypothetical protein, conserved Tb11.02.2810 Positives = 330/334 (98%)
up6F1 hypothetical protein, conserved Tb11.01.0950 Positives = 998/1065 (93%)
up6G5 hypothetical protein, conserved Tb927.10.14430 Positives = 813/1014 (80%) 2 TMDs
up7B4 hypothetical protein, conserved Tb927.4.1320 Positives = 381/387 (98%)
up7C8 succinyl-coA:3-ketoacid-coenzyme A transferase, putative Tb11.02.0290 Positives = 35/37 (94%)
up7D2 hypothetical protein, conserved Tb927.5.2610 Positives = 225/225 (100%)
up7F4 hypothetical protein, conserved Tb11.01.6610 Positives = 300/333 (90%)
up7G4 variant surface glycoprotein, pseudogene Tb11.v4.0020 Positives = 162/238 (68%)
up7G9 hypothetical protein, unlikely Tb09.160.0590 Positives = 69/69 (100%) SP, 3 TMDs
up7G10 variant surface glycoprotein, pseudogene Tb11.57.0045 Positives = 198/267 (74%) 
up7H12 expression site-associated gene, pseudogene Tb927.2.910 Positives = 571/1006 (56%) 
up8A12 hypothetical protein, conserved Tb927.6.620 Positives = 102/102 (100%)
up8B11 hypothetical protein, conserved Tb11.02.2810 Positives = 284/286 (99%)
 up8B12 variant surface glycoprotein-related, putative Tb09.244.2240 Positives = 219/294 (74%) 
up8C12 hypothetical protein, conserved Tb927.3.1550 Positives = 114/114 (100%)
up8D9 hypothetical protein, conserved Tb927.4.1320 Positives = 344/387 (88%)
up8F10 leucine-rich repeat protein, putative Tb927.3.1490 Positives = 136/137 (99%) 
up8F12 hypothetical protein Tb927.3.1230 Positives = 379/393 (96%)
up8G8 hypothetical protein,chrXI additional, unordered contigs Tb11.1770 Positives = 247/293 (84%) 
up8H7 hypothetical protein, conserved Tb927.4.1320 Positives = 121/148 (81%)
up8H10 SL RNA Tb09_SLRNA_0004 Positives = 55/58 (94%) 
up8H11 RNA-editing complex protein,KREPB6 Tb927.3.3990 Positives = 74/74 (100%)
up9B9 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase Tb10.v4.0244 Positives = 258/264 (97%) 
up9B12 hypothetical protein, unlikely Tb09.160.0590 Positives = 51/53 (96%) SP, 3 TMDs
up9D12 hypothetical protein, conserved Tb927.5.2610 Positives = 208/221 (94%)
up9E4 ARP2/3 complex subunit, putative Tb927.2.2900 ositives = 530/546 (97%)
up9H2 hypothetical protein, conserved Tb927.5.3550 Positives = 688/740 (92%) SP
up10C8 hypothetical protein, conserved Tb09.244.0440 Positives = 62/81 (76%) 
up10F1 Variant surface glycoprotein, pseudogene Tb09.160.0220 Positives = 812/895 (90%) 
up10F2 helicase, putative Tb927.5.3940 Positives = 77/96 (80%)
up10F8 hypothetical protein, unlikely Tb09.160.0590 Positives = 64/65 (98%) SP, 3 TMDs
up10G2 hypothetical protein, conserved Tb11.18.0010 Positives = 108/110 (98%) SP, 7 TMDs
up10G9 hypothetical protein, unlikely Tb09.160.0590 Positives = 64/65 (98%) SP, 3 TMDs
up10H8 retrotransposon hot spot protein, pseudogene Tb927.1.240 Positives = 764/846 (90%) 
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Table 6.2: Genes Isolated Multiple Times. Gene annotations, TriTryp gene IDs, 
and number of isolated clones.  
Gene Annotation TriTryp Gene ID # of hits
hypothetical protein, conserved Tb927.4.1320 32
hypothetical protein, conserved Tb11.02.2810 17
hypothetical protein, unlikely Tb09.160.0590 4
hypothetical protein, conserved Tb11.01.0950 4
hypothetical protein, unlikely Tb927.1.200 3
hypothetical protein, unlikely Tb09.160.1350 2
hypothetical protein, conserved Tb11.01.5780 2
hypothetical protein, conserved Tb11.01.6610 2
hypothetical protein, conserved Tb11.18.0010 2
hypothetical protein, unlikely Tb927.1.460 2
hypothetical protein, conserved Tb927.5.2610 2
hypothetical protein, conserved Tb927.7.6550 2
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Figure 6.1: FA Uptake RNAi Screen Flowchart.  
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Figure 6.2: FA Uptake in Clones Isolated From the Screen. 29-13 parental 
cell lines and clonal parasite populations isolated from the screen were grown in 
uninduced or induced conditions for 4 (A) or 6 (B) days and assayed for uptake 
of [3H]-C12. All values are expressed as a percentage of uninduced (black bars) 
or 29-13 (grey bars) controls. 
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Figure 6.3: FA Uptake in Independently Constructed RNAi Parasites. 
Independently constructed RNAi parasites were grown in uninduced or induced 
conditions for 4 (black bars) or 8 (grey bars) days and assayed for uptake of B-
C12. All values are expressed as a percentage of uninduced controls. 
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CHAPTER 7 
 
CONCLUSIONS 
 
Lipid metabolism in Trypanosoma brucei is an often-overlooked aspect of 
the parasite’s biology. The existing body of research is outstanding and provides 
a solid theoretical and methodological foundation on which to design future 
studies. However, many genes that are likely involved in lipid metabolism remain 
unstudied. This is surprising because of the unique and essential nature of these 
metabolic pathways. The parasite’s utilization of microsomal elongases as a de 
novo fatty acid synthesis pathway is novel and many of the characterized genes 
represent potential drug targets. 
The research I have presented in this dissertation has added to our 
growing knowledge of Trypanosoma brucei’s lipid metabolism. In the process we 
have established acetyl-CoA carboxylase (ACC) as a potential drug target. 
Knockdown of ACC caused a doubling in the mean time until death in a mouse 
model. However, we did not cure the mice of the infection and they eventually 
succumbed. In the future, conditional knockouts for ACC should be generated 
and tested for virulence in mice.  
Beyond adding to a long list of potential drug targets, our study has also 
demonstrated the importance of experimental flexibility when investigating 
potentially essential genes. Many investigations of individual genes and even 
genetic screens targeting essential genes examine parasite growth in normal 
culture media. This methodology leaves many essential genes unidentified. I 
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realize that investigating each gene’s contribution to virulence in a mouse model 
is not feasible and would be a foolish endeavor. Instead, media components can 
be altered to more closely mimic physiological conditions in the mammalian 
bloodstream and cerebrospinal fluid. I fully anticipate that subtle changes in 
media composition would influence the outcome of many experiments. 
As a follow-up to the ACC characterization, the consequences of ACC 
knockdown by RNA interference should be defined. This is the focus of an 
ongoing project in the lab. The metabolic or functional consequences of ACC 
RNAi, rather than loss of ACC, were the direct causes of reduced parasite 
virulence. Defining these consequences would allow us to expand our 
investigation to other genes potentially involved in that particular cellular process. 
For example, if we determine that ACC RNAi causes of reduced endocytosis 
rates, other genes involved in endocytosis could potentially result in a similar 
reduction in parasite virulence.   
This concept is not unique, as many researchers attempt to identify the 
cause of cell death brought on by RNAi. However, because RNAi of most 
essential genes results in cell death in vitro, this endeavor is often fruitless. When 
a cell is dying, it becomes difficult to define whether a phenotype is a cause, 
direct consequence, or indirect consequence of cell death. In the case of ACC 
we can avoid this potential problem because the gene is essential for growth only 
under certain conditions. Thus, the elaborated phenotypes brought on by RNAi of 
ACC can be studied in isolation of cell death. 
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 I hope that the information and thoughts I have shared in this dissertation 
will be useful to future researchers. With a little hard work and a lot of luck this 
work could lead to a treatment for African trypanosomiasis, resulting in the 
economic revitalization of Sub-Saharan Africa, a region of the world too long 
oppressed by the shadow of the tsetse.         
 
 
 
 
 
 
